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 ABSTRACT 
 
Anxiety and depression are common comorbidities in people with chronic obstructive 
pulmonary disease (COPD), contributing to greater morbidity and mortality in an 
already vulnerable population. Despite the prevalence, few recommendations exist in 
global management guidelines for the detection and treatment of these comorbidities, 
reflecting the limited literature available on effective strategies for dealing with mental 
health issues in COPD populations. There is promising evidence that cognitive 
behavioural therapy (CBT) improves mental health outcomes in people with COPD. 
However, investigational studies have commonly reported participants’ lack of 
transport, lack of time and illness as barriers to recruitment and successful completion. 
This thesis was undertaken in response to a need identified in the literature for an 
alternative modality of CBT delivery for people with COPD suffering from psychological 
symptomatology. Thus, a novel home-based self-management CBT learning resource in 
a DVD format was developed with an accompanying manual. To investigate the 
primary aim of this thesis, a randomised controlled trial called the ‘Breathing New Life’ 
study was conducted to determine the efficacy of CBT to treat anxiety and depression 
in people living with COPD via two formats: group therapy with a reduced number of 
sessions or this novel home-based self-management DVD resource, compared to usual 
care. The secondary aim was to investigate the efficacy of these interventions on 
improvement in health-related quality of life (HRQoL).  
 
This thesis is presented as a series of papers (i.e. PhD with publication) from data 
collected from the Breathing New Life study (ACTRN12616001039471). Study One 
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investigates the risk factors associated with concomitant anxiety and depression and 
found younger age and having no previous psychological medical history were risk 
factors for psychological symptomatology compared to those without psychological 
symptomatology. Study Two investigates the most suitable screening tool for detecting 
clinically significant anxiety and depression in COPD populations and found simple 
modifications to the commonly used Hospital Anxiety and Depression Scale (HADS) 
improved optimal sensitivity and specificity, whilst the Beck Inventories had acceptable 
sensitivity and specificity without any modifications. Study Three reports the results 
from the randomised controlled trial investigating the efficacy of CBT delivered in the 
two different formats. No significant differences over time between those receiving 
CBT and usual care for anxiety, depression or HRQoL were found in this COPD cohort. 
However, opinions of benefit expressed in Study Four—a qualitative investigation into 
the facilitators and barriers COPD participants face when enrolling and completing 
CBT—provide support that this population find CBT useful, despite being unable to 
detect any measureable difference.   
 
Globally, this thesis adds new knowledge to the body of literature supporting the 
importance of early screening and treatment for psychological symptomology in 
people living with COPD. Despite the inability of CBT to improve anxiety and 
depression, findings from this thesis have important implications towards industry 
discussion surrounding routine screening for concomitant anxiety and depression, the 
continued use of the HADS and Beck Inventories as appropriate screening tools in 
COPD populations and how best to engage and retain COPD participants in CBT.  
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 CHAPTER ONE 
 
1 INTRODUCTION 
  
1.1 COPD 
Chronic obstructive pulmonary disease (COPD) is typically a progressive lung disease 
defined by persistent airflow limitation, classically caused by an enhanced chronic 
inflammatory response of the respiratory system to noxious particles or gases. 
Prolonged exposure to inhaled irritants is the most common cause of developing 
COPD, with the primary risk factor being exposure to tobacco smoke. Indoor air 
pollution (e.g. fuels used for cooking and heating) and having a genetic predisposition 
(most commonly an alpha-1 antitrypsin deficiency) have also been identified as major 
risk factors. The characteristic symptoms of COPD include dyspnoea, chronic cough 
and sputum production (1). Prolonged exposure to inhaled irritants results in an influx 
of inflammatory cells such as neutrophils, macrophages and CD8+ T-lymphocytes 
which then initiates an inflammatory cascade that activates the release of cytokines, 
including tumour necrosis factor alpha, interferon gamma, interleukins (IL-1, IL-6, IL-8), 
C-reactive protein, matrix-metalloproteinases (MMP-6, MMP-9) and fibrinogen (2). 
These processes sustain the amplified chronic inflammatory response observed in 
COPD which results in a combination of parenchymal tissue damage (emphysema), 
mucociliary dysfunction and numerous structural changes in the lung (obstructive 
bronchiolitis), propagating airflow limitation (2, 3). 
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COPD is a leading cause of morbidity and mortality worldwide; it is currently estimated 
that 65 million people suffer from moderate to severe COPD. Although COPD is a 
preventable disease, it is predicted to become the third leading cause of death globally 
by 2030 (4). In Australia, one in five persons over the age of 45 have COPD and the 
latest data available from 2014 estimated 7,025 deaths eventuated as a result of this 
comborbidity—making COPD the fifth leading cause of death (5). However, it is often 
argued the prevalence of COPD is underestimated for a number of reasons, including: 
the slow nature of COPD development delaying diagnosis until people exhibit 
moderate symptoms, experience exacerbations or become disabled; misdiagnosis as 
asthma; and people mistaking their COPD symptoms as signs of ageing or lack of 
fitness (6). 
 
1.2 The problem 
Whilst COPD primarily affects the airways and lungs, it also has significant systemic 
consequences which affect quality of life and survival (1, 7). People living with COPD 
may also suffer from co-morbid cardiovascular disease, osteoporosis, lung cancer, 
sleep-related breathing disorders as well as metabolic syndrome and diabetes (1). 
These comorbidities may develop independently of a diagnosis of COPD, be related to 
the disease via similar risk factors or one disease increases the risk of developing 
another. A major non-systemic comorbidity people with COPD may experience is 
psychological distress, in particular anxiety disorders and depression—estimated to 
occur in 36% and 40% of people with COPD, respectively (8-10). Research indicates 
COPD populations are at a higher risk of developing these psychological comorbidities 
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than the general population and those with other chronic diseases such as 
cardiovascular disease and renal disease (9, 11-13). People with COPD suffering from 
anxiety or depression have poorer outcomes across a number of health domains, 
including: increased exacerbation rates (14-16); diminished exercise performance and 
functional mobility (11, 14, 17); poorer health-related quality of life (HRQoL) (16-18); 
more emergency hospital visits, hospitalisations and lengths of stay as an admitted 
patient (11, 16, 19) and greater mortality rates (11, 20, 21). Consequently, people with 
COPD that also suffer from anxiety or depression are a greater economic burden than 
those that do not have any psychological symptomatology (22-24). 
 
Despite this public health problem, there are few recommendations in the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) management guidelines for the 
treatment of these psychological comorbidities, reflecting the limited literature 
available on the efficacy of treatment options (1). There is promising evidence to 
suggest cognitive behavioural therapy (CBT) improves mental health outcomes in 
COPD populations (25-38). CBT is a psychological intervention generally run over 12 
weeks, conducted face-to-face individually or in groups which aims to change the 
distorted, unrealistic thinking and negative behaviour patterns thought to contribute 
to psychological symptomatology (39-42). However, an ongoing problem with CBT 
intervention studies in COPD populations are the low recruitment rates of 13–49% (28, 
31, 35, 36, 43) and high attrition rates of 27–47% often reported (28, 32, 44). Possible 
solutions could be to reduce the number of face-to-face group CBT sessions or to 
eliminate the necessity for attending face-to-face sessions. However, there is a need to 
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build upon the limited data currently available to establish the effectiveness of home-
based, self-management CBT programs for improving anxiety and depression in people 
with COPD. Furthermore, as few studies report the reasons why participants drop out 
of CBT, an exploration of the facilitators and barriers people with COPD face with this 
type of therapy is warranted to help better explain and improve the rate of uptake and 
completion of CBT. 
 
The GOLD guidelines also lack clear recommendations on how to identify anxiety and 
depression in people with COPD. This has important implications for the timely 
identification and treatment required to reduce the additional morbidity and mortality 
these comorbidities have on an already vulnerable population. The Hospital Anxiety 
and Depression Scale (HADS), the Beck Anxiety Inventory (BAI) and the Beck 
Depression Inventory (BDI-II) are commonly used screening tools to assess the 
presence of psychological symptomatology in people with COPD. However, the HADS 
has only been validated for use in this population in two previous studies (45, 46), 
whereas no previous studies have validated the Beck Inventories, prompting the need 
for an investigation into the suitability of these measures in COPD populations.  
 
Whilst early detection is vital for early intervention, preventing the onset of anxiety 
and depression in people with COPD in the first place is a fundamental public health 
approach to reduce the health services required to ameliorate the morbidity and 
mortality associated with these comorbidities. This involves reducing exposure to 
modifiable risk factors for psychological symptomatology as well as enhancing the 
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protective factors that promote good mental health and wellbeing. Despite the known 
benefits of prevention, the GOLD guidelines do not specify any strategies to decrease 
the incidence of anxiety and depression in people with COPD.  
 
1.3 Research aims 
The research conducted for this thesis aimed to add evidence to each stage of the 
conceptual framework (Figure 1.1) used by allied health professionals to improve the 
morbidity and mortality associated with anxiety and depression in COPD populations. 
This thesis primarily sought to investigate the efficacy of CBT in addition to usual care 
for the treatment of anxiety and depression in people living with COPD, compared to 
usual care alone (UC). CBT was delivered via a traditional group therapy format (CBT) 
with a reduced number of face-to-face sessions relative to previous programs (25, 27-
34, 44, 47, 48), or a home-based self-management DVD format (DVD), with efficacy of 
both assessed by the level of psychological symptomatology. A randomised controlled 
trial was conducted (hereafter referred to as the ‘Breathing New Life’ study) to 
investigate this primary aim. The secondary aim of this thesis was to investigate the 
efficacy of these CBT interventions to improve HRQoL relative to usual care. This thesis 
also sought to investigate the risk factors associated with psychological 
symptomatology, the most suitable tool(s) for screening anxiety and depression and to 
explore participants’ experiences of CBT to understand the enablers and disablers for 
people with COPD to successfully enrol and complete a course.   
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*Note: investigations conducted in this thesis are outlined in red 
Figure 1.1 A conceptual framework (developed by the candidate) for reducing disease-
related morbidity and mortality  
 
1.4 Thesis outline 
This thesis is presented as a series of papers addressing the research aims utilising data 
collected from the Breathing New Life study (Clinical Trial Registration Number: 
ACTRN12616001039471). Edith Cowan University (ECU) supports the submission of 
PhD theses that comprise a series of papers prepared for publication. ECU’s 
Requirements of a Thesis with Publication, 2017 guidelines outline that the submitted 
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thesis can consist of publications that have already been published, are in the process 
of being published, or a combination of these (49). These guidelines also state that the 
number of publications submitted will vary between disciplines and projects, but 
should be sufficient for the body of work to constitute a substantial and original 
contribution to knowledge (49). 
 
This structure has been adopted by the candidate in the submission of this thesis. As 
such, while the theory linking the studies/papers should be clear for the examiner, 
each study must be stand-alone in content. Consequently, theses submitted as a series 
of papers sometimes suffer from repetition of literature and methodology from study 
to study. 
 
1.4.1 Study One 
Determinants of concomitant anxiety and depression in people with chronic obstructive 
pulmonary disease  
The primary aims of this study were to investigate the prevalence and determinants of 
concomitant anxiety and depression in people diagnosed with COPD. It was predicted 
previous risk factors identified separately for anxiety or depression in people with 
COPD were also shared risk factors for concomitant anxiety and depression. The risk 
factors found for this COPD cohort adds to the limited data available on potential 
protective factors to concomitant psychological symptomatology. 
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1.4.2 Study Two 
Discriminant validity of the Hospital Anxiety and Depression Scale, Beck Depression 
Inventory (II) and Beck Anxiety Inventory to confirmed clinical diagnosis of depression 
and anxiety in patients with chronic obstructive pulmonary disease 
The aims of this study were to investigate the discriminant validity of the Hospital 
Anxiety and Depression Scale (HADS) with people diagnosed with COPD, and to 
examine the discriminant validity of the Beck Depression Inventory (BDI-II) and Beck 
Anxiety Inventory (BAI) as potential alternatives for this population. It was pedicted 
the BDI-II and BAI may be better alternatives for screening people with COPD for 
psychological symptomology than the HADS. As there are limited data currently 
available on the validity of commonly used screening tools for psychological 
symptomatology in people with COPD, the information gathered from this research 
adds to the body of literature and provides a foundation for recommendations on the 
most appropriate tool(s). 
 
1.4.3 Study Three 
A randomised controlled trial investigating the efficacy of cognitive behavioural 
therapy on the mental health of people with chronic obstructive pulmonary disease: the 
‘Breathing New Life’ study  
The primary aim of this study was to investigate the efficacy of CBT in addition to usual 
care, to reduce anxiety and depression symptomatology in people living with COPD. 
CBT was provided via a traditional group therapy format (CBT) with a reduced number 
of sessions relative to previous programs, or a home-based self-management DVD 
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format (DVD), compared to usual care alone (UC). The secondary aim was to 
investigate the subsequent effect of these CBT interventions on HRQoL.  
 
The study hypotheses were:  
 People with COPD receiving either format of CBT intervention would 
demonstrate lower rates of anxiety and depression symptoms after 12 months 
compared to participants in the usual care group (UC). Moreover, the DVD 
group would have higher compliance rates during the intervention period than 
the face-to-face CBT group due to the more convenient nature of the DVD 
resource 
 COPD participants in either CBT interventions would also demonstrate 
improvements in HRQoL compared to participants in the UC group 
 
There is currently no consensus which is the most effective treatment for anxiety and 
depression in people with COPD. However, there is emerging data on the effectiveness 
of home-based self-management programs. This research investigated the efficacy of a 
novel self-management CBT resource to treat anxiety and depression, in the hopes 
that the DVD could eventually become a stand-alone resource. 
 
1.4.4 Study Four 
A qualitative investigation of the facilitators and barriers for people with chronic 
obstructive pulmonary disease to participate in cognitive behavioural therapy 
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The aim of this study was to investigate the facilitators and barriers to successful 
completion of CBT, delivered either as traditional face-to-face group sessions or a 
home-based self-management DVD resource. The information gathered from the first-
known qualitative investigation of the enablers and disablers for COPD participants 
towards CBT will help future studies optimise development of their CBT interventions 
to improve future uptake and retention in order to ultimately improve mental health 
outcomes in people with COPD. 
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CHAPTER TWO 
 
2 REVIEW OF THE LITERATURE 
 
2.1 Anxiety and depression 
Anxiety is an emotion characterised by somatic symptoms of tension and behavioural 
disturbances due to the apprehensive anticipation of future danger or misfortune. The 
Diagnostic and Statistical Manual of Mental Disorders (5th edition, DSM-V) defines the 
types of anxiety disorders as follows: separation anxiety disorder, selective mutism, 
specific phobia, social anxiety disorder, panic disorder, panic attack specifier, 
agoraphobia, generalised anxiety disorder, substance/medication-induced anxiety 
disorder, anxiety disorder due to another medical condition, other specified anxiety 
disorder and unspecified anxiety disorder (50). Whilst each specific anxiety disorder 
has slightly different symptoms, they all share the common themes of excessive, 
irrational fear and dread (50). In Australia, the latest figures from the 2014–2015 
National Health Survey report the 12 month prevalence of anxiety-related conditions 
to be 11.2% (2.6 million people) (51).  
 
Depression is “the presence of sad, empty or irritable mood, accompanied by somatic 
and cognitive changes that significantly affect the individual’s capacity to function” 
(p155) (50). The Diagnostic and Statistical Manual of Mental Disorders (5th edition, 
DSM-V) defines the types of depressive disorders as follows: disruptive mood 
dysregulation disorder, major depressive disorder, persistent depressive disorder 
(dysthymia), premenstrual dysphoric disorder, substance/medication-induced 
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depressive disorder, depressive disorder due to another medical condition, other 
specified depressive disorder, and unspecified depressive disorder (50). What differs 
amongst the depressive disorders are specifications of duration, timing or presumed 
aetiology (50). The Australian 2014–2015 National Health Survey reports the 12 month 
prevalence of mood disorders (which includes depression) as 9.3% (2.1 million people) 
(51). It is estimated approximately one in twenty Australians (5.1%) have both an 
anxiety-related condition and a mood disorder (51). 
 
2.2 Negative impact of anxiety and depression  
People with chronic obstructive pulmonary disease (COPD) suffering from anxiety and 
depression have poorer health outcomes compared to those without these 
psychological comorbidities. Further adding to the debilitating nature of COPD, people 
with anxiety and depression symptomatology experience more frequent exacerbations 
(14-16); reduced functional mobility and exercise performance (e.g. less laps achieved 
during the six-minute walk distance test) (11, 14, 17); poorer health-related quality of 
life (HRQoL) (16-18); increased hospital emergency department visits, increased 
hospital admissions  and  increased lengths of hospital stays (11, 16, 19); and greater 
mortality rates (11, 20, 21). In addition, people with COPD that suffer from 
psychological symptomatology are also a greater economic burden through increased 
expenditure to health and welfare systems, and lost productivity due to lower 
employment, absenteeism and premature death (22-24). Early detection of anxiety 
and depression in people with COPD is essential in order to appropriately manage the 
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comorbidities at the earliest possible stages to reduce the already high rates of 
morbidity and mortality in people with COPD. 
 
2.3 Risk factors 
Several risk factors have been identified to increase the likelihood of developing 
anxiety or depression symptomatology in people with COPD. Shared risk factors for 
either anxiety or depression commonly reported in the literature include severe 
dyspnoea, poor HRQoL, smoking, lower education levels, lower socioeconomic status 
and having other non-psychological comorbidities (52-55). Other determinants 
commonly but inconsistently reported include age (some studies suggesting younger 
COPD populations, whilst others suggest older COPD populations are at greater risk), 
being female, having lower values for forced expiratory volume (FEV1) and greater 
severity of COPD (52-54, 56-59). Unique determinants associated with depression 
include living alone and not being married (53, 54). There appear to be no unique risk 
factors that contribute to people with COPD having anxiety symptomatology alone. 
However, there are limited data available on risk factors associated with concomitant 
anxiety and depression in people with COPD. It would be reasonable to assume that 
the majority of the risk factors identified in the literature for anxiety or depression are 
also shared risk factors for concomitant anxiety and depression but this remains to be 
determined.   
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2.4 Prevalence  
The estimated prevalence of anxiety and depression in people with COPD varies 
greatly, with estimates for anxiety ranging anywhere from 2–96% and from 8–88% for 
depression (9, 60-63). A meta-analysis of reported prevalence of anxiety disorders and 
depression in COPD patients, conducted by Yohannes et al. (2010) calculated a 
standard measure of effect size for n=13 previous studies and used weighted pooled 
estimates to suggest a mean prevalence of 36% for anxiety and 40% for depression can 
be used as a clinical benchmark of prevalence estimates in people with COPD (10). The 
majority of studies included in the meta-analysis used self-report screening tools 
rather than diagnostic clinical interviews.   
 
Another systematic review (n=10 included studies) reported the prevalence of clinical 
anxiety to be 10–55% amongst COPD in-patients and 13–46% amongst out-patients 
(62). The greatest strength of this review is that all the included studies diagnosed 
anxiety disorders via a clinical interview using a recognised, industry standard format 
(DSM-IV or previous versions or International Classification of Disease and Related 
Health Problems, 10th edition (ICD-10)). For depression, a systematic review found that 
those with COPD had a higher prevalence of depressive symptoms than healthy 
controls; 24.6% (95% CI: 20.0–28.6%) in COPD patients compared to 11.7% (95% CI: 
9.0–15.1%) in controls (63). The strength of this review was that a comprehensive 
meta-regression analysis and subgroup effect size analysis was performed to 
determine the prevalence of depression. However, limitations of this review include 
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the fact that depression was assessed by a variety of measures rather than via 
diagnostic clinical interviews, and the number of studies included was small (n=8). 
 
The large variation in data may be attributed to a number of methodological 
discrepancies. Method of psychiatric diagnoses vary greatly, with the majority of 
studies utilising self-report questionnaires as opposed to diagnostic clinical interviews. 
An overlap between somatic symptoms of anxiety and depression with those of COPD 
also complicates diagnoses. Screening measures used to detect depression in the 
elderly may be less precise due to the overlap of somatic symptoms and those that 
occur due to the ageing process. Furthermore, differing degrees of COPD severity, 
differing study settings (e.g. clinical populations vs. community based patients) and 
sample sizes all contribute to the variations in prevalence figures.  
 
In Australia, there is a paucity of data available on the prevalence of anxiety and 
depression in people with COPD. To date, only three published studies have 
investigated the prevalence of these comorbidities. The first, by Livermore et al. (2010) 
reports that 19% of participants (n=10 out of 52) were clinically diagnosed with panic 
attacks, 17% of participants (n=9 out of 52) with panic disorder and 4% with major 
depression using the Anxiety Disorders Interview Schedule of the DSM-IV (ADIS-IV) 
(33). Panic attacks and panic disorder fall under the larger umbrella of anxiety 
disorders, but do not represent all other types of anxiety disorders in Australia. The 
second study by Doyle et al. (2013) screened for anxiety and depression using the self-
report Hospital Anxiety and Depression Scale (HADS) and found 27.2% of participants 
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reported symptoms for anxiety and 20.4% reported symptoms for depression (64). The 
last study by Walters et al. (2013) also utilised the HADS and found 40% of participants 
reported symptoms of anxiety and 20% reported symptoms of depression (36). 
Although there are large variations in the prevalence of anxiety and depression in all 
three studies, these Australian rates fall within the scope of other international 
estimates (9, 60-63).  
 
2.5 Screening for anxiety and depression 
A wide range of measures have been reported in the literature for detecting the 
presence of anxiety or depression in people with COPD (Table 2.1). The majority of 
these measures are self-report screening tools which identify the presence of clinically 
significant levels of anxiety or depression symptomatology. A clinical diagnosis of 
anxiety or depression is determined via a structured clinical interview which meets The 
Diagnostic and Statistical Manual of Mental Disorders or the International 
Classification of Diseases and Related Health Problems criteria. The distinction 
between the types of measures used in the literature is important, as the majority of 
studies examining the prevalence of anxiety and depression in people with COPD have 
utilised self-report measures which indicate rates of clinically significant distress levels 
rather than provide an actual clinical diagnosis through a psychologist or psychiatrist. 
Benefits of using self-report questionnaires include the low costs involved, the 
relatively short time it takes to complete, either patients or health service providers 
can complete the questionnaires, the questionnaires are extremely easy to administer, 
and they can be adapted and validated for specific populations. However, a 
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disadvantage of using self-report measures is the potential for inflated misdiagnosis 
due to the overlap of somatic symptoms typical of COPD with those of anxiety or 
depression. Narrow time-frames for reporting of symptoms (e.g. over the past week or 
two weeks) are also a limitation of these types of measures as psychological conditions 
can be missed.  
 
The current Global Initiative for Chronic Obstructive Lung Disease (GOLD) management 
guidelines lack recommendations for the screening and treatment of psychological 
comorbidities in people with COPD (1). Consequently, screening for mental health 
symptomatology in COPD populations has not become standard practice and there is a 
lack of consensus with respect to the most appropriate tool/s for measurement of 
these symptoms.  This is likely to result in a lack of timely and effective treatment for 
those suffering from these comorbidities. The GOLD guidelines do acknowledge the 
“Hospital Anxiety and Depression Scale (HADS) and the Primary Care Evaluation of 
Mental Disorders (PRIME-MD) Patient Questionnaire [screening tools] have been used 
to improve identification and treatment of anxious and depressed patients” (p90) (1). 
Indeed the HADS is one of the most commonly cited screening tools used in COPD 
studies (11, 16, 19, 41, 45-47, 56, 65-74) but only two published papers have 
established its validity for use in this population (45, 46). The Beck Anxiety Inventory 
(BAI) and Beck Depression Inventory (BDI-II) are also popular screening tools 
commonly used in the literature to measure anxiety or depression respectively (26-28, 
31, 32, 37, 48).  
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Table 2.1 Diagnostic and screening measures used to detect anxiety and depression in 
people with COPD  
Structured Clinical Interviews 
Anxiety Disorders Interview Schedule (ADIS) 
Composite International Diagnostic Interview (CIDI) 
Diagnostic Interview for Psychiatric Disorders (DIPS) 
Geriatric Mental State Schedule (GMS) 
International Statistical Classification of Diseases and Health Related Problems (ICD) 
Mini International Neuropsychiatric Interview (MINI) 
Structured Clinical Interview for DSM Disorders (SCID) 
World Mental Health Composite International Diagnostic Interview (WMH-CIDI) 
Screening Measures 
Anxiety and Depression 
Edmonton Symptom Assessment Scale (ESAS) 
Geriatric Mental State Schedule 
Hospital Anxiety and Depression Scale (HADS) 
Kellner’s Symptom Questionnaire (SQ) 
Primary Care Evaluation of Mental Disorders (PRIME-MD) 
Profile of Mood States (POMS) 
Symptom Checklist-90-R (SCL-90-R) 
Anxiety 
Beck Anxiety Inventory (BAI) 
Geriatric Anxiety Inventory (GAI) 
Manifest Anxiety Scale (MAS) 
Spielberger State Trait Anxiety Inventory (STAI) 
Depression 
Beck Depression Inventory (BDI-II) 
Brief Assessment Schedule for Depression Cards (BASDEC) 
Centre for Epidemiologic Studies Depression Scale (CES-D) 
Geriatric Depression Scale (GDS) 
Montgomery–Åsberg Depression Rating Scale (MADRS) 
Zung Self-Rating Depression Scale (ZDS) 
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2.6 Mechanisms  
The mechanism(s) that lead to anxiety and depression in people with COPD are still 
largely unknown and poorly understood. It is unclear whether the onset of 
psychological symptomatology is a result of the disease itself or due to pre-existing 
mental health conditions prior to developing COPD. Several theoretical models have 
been proposed for the development of anxiety and depression disorders in the general 
population and these have also been applied in COPD populations which are 
summarised below.  
 
2.6.1 Mechanisms for anxiety  
As dyspnoea and hyperventilation are recurrent symptoms commonly suffered by both 
people with COPD and panic anxiety, a number of models have been suggested to 
explain the possible shared pathophysiology. These models arise from the literature 
surrounding mechanisms for anxiety in people with COPD which mainly describes 
panic anxiety; the literature surrounding mechanisms for other anxiety conditions is 
presently lacking. 
 
2.6.1.1 The hyperventilation model  
The hyperventilation model assumes that panic, anxiety and dyspnoea arise from the 
same clinical presentation, i.e. the hyperventilation syndrome whereby symptoms 
such as dyspnoea, heart palpitations and chest pain exist but there are no other 
causes. People with COPD and anxiety generally have dysfunctional ventilator patterns 
which may be connected with hyperventilation. The resultant hypocapnic alkalosis 
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may then be responsible for certain symptoms of anxiety and dyspnoea, thereby 
producing an exacerbated response (75). 
 
2.6.1.2 The carbon dioxide hypersensitivity model 
The carbon dioxide hypersensitivity model is based on the idea that people with COPD 
suffering from panic disorder have an abnormally sensitive brainstem respiratory 
control mechanism. The pathophysiological mechanism is unclear but it is theorised 
that in response to increased carbon dioxide or lactate, abnormally sensitive brainstem 
chemoreceptors elicit a ‘suffocation false alarm’ when impending challenges to 
suffocation occurs, provoking hyperventilation and a fear of dyspnoea leading to a 
panic attack (76). It is proposed that both carbon dioxide and lactate share 
mechanisms of action, suggesting a physiological and neuroanatomical overlap.  
 
2.6.1.3 The cognitive behavioural model   
The cognitive behavioural model (also known as ‘Clark’s cognitive model’ or the 
‘dyspnoea-fear theory’) is the most widely accepted theory for the occurrence of panic 
attacks and panic disorder in physically healthy adults. The model is based on the idea 
that fear and misinterpretation of physical experiences induced by dyspnoea and 
hyperventilation catalyses a panic reaction (77). The cognitive behavioural model has 
also emerged as the most widely accepted theory for the onset of anxiety in people 
with COPD, as somatic symptoms of anxiety are similar to those associated with the 
lung disease. It is hypothesised that people with COPD misconstrue the severity of 
their dyspnoea through catastrophic cognitions. This fear of severe breathlessness 
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leads to a heightened state of psychological arousal, resulting in further 
misinterpretation of increased dyspnoea and worsening of breathlessness due to 
hyperventilatory panic attacks, i.e. a positive feedback loop is created (78). It has been 
hypothesised that people with COPD with regular catastrophic thoughts about 
symptoms have an increased risk of anxiety compared to those who do not have these 
regular invasive thoughts (41, 42, 79, 80). 
 
2.6.1.4 The stress model 
The most recent theory which has emerged explores the relationship between stress 
and anxiety. Pate and Davenport (2013) propose the notion of constant tracheal 
occlusion stimulating the persistent release of the stress hormone cortisone which 
promotes anxiety (81). Supporting evidence for this proposal comes from the measure 
of cortisone in mice where the trachea was occluded. This study found that when mice 
were tracheal occluded to mimic the recurrent airway obstruction experienced by 
people with COPD, they had a higher release of cortisone. Therefore, it is hypothesised 
that people with COPD experience both a psychological and a systemic stress.  
 
2.6.1.5 Smoking 
The relationship between smoking and nicotine use in people with COPD and anxiety is 
complex, with both anxiogenic and anxiolytic effects being found (60, 82). Support for 
this complex pathogenesis comes from studies of general population smokers who 
have higher lifetime prevalence rates of anxiety disorders and those with a history of 
anxiety disorders reporting more severe nicotine withdrawal symptoms (83, 84). These 
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results suggest nicotine may induce anxiety or people with COPD susceptible to anxiety 
use nicotine for its sedative effect during heightened states of psychological arousal. 
Furthermore, nicotine withdrawal may mimic anxiety symptomatology and people 
with COPD smoke to help alleviate these feelings.  
 
2.6.2 Mechanisms for depression  
The pathogenetic mechanisms of comorbid depression in COPD are also poorly 
understood. Three prevailing biological factors have been put forward as the causes of 
depression in people with COPD: smoking, hypoxia and exacerbation of COPD (59, 60, 
85, 86). The impact of illness on patients’ lives has also been theorised as a 
contributing factor to the onset of depression. These theories are briefly described 
below. 
 
2.6.2.1 Biological mechanisms 
Smoking is a risk factor for depression in people with COPD, with depression playing a 
role in the initiation and maintenance of smoking, smoking being the primary risk 
factor for developing COPD, and COPD in turn contributing to the aetiology of 
depression (86). However, smoking also appears to play a complex pathogenic role via 
the hypoxia generated as a result of smoking. Hypoxia is a consequence of both 
smoking and COPD and known to induce neuropsychiatric disturbances such as 
psychomotor slowing, memory impairment and depressed mood (56). Various 
pathogenetic mechanisms have been suggested, including vascular endothelial 
damage, direct damage of white matter in the brain and oxidative stress (56). 
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Inflammatory biomarkers have also been postulated to contribute to the onset of 
depressive symptomatology in people with COPD due to the link between the 
characteristic chronic inflammation of the respiratory system and exacerbations seen 
in this disease. People with COPD and depression suffer from increased exacerbation 
rates (14-16) and support for the shared inflammation pathway theory comes from 
findings of depression being associated with impaired immune function (87-89), 
increasing susceptibility to infections (90) and thus infective exacerbations in COPD 
populations (91, 92).  
 
2.6.2.2 Impact of COPD 
The impact of a chronic illness on peoples’ lives has been theorised as a complex 
contributing factor to the onset of depression. Norwood (2007) summarises this 
complex relationship into three domains: loss of functionality, increased burden on 
internal coping mechanisms and perceived social support (86). People with COPD may 
experience a lack of mobility, an inability to physically perform previous occupational 
activities or participate in recreational activities, and may require the use of oxygen 
therapy. Norwood states “the psychological losses attached to each of these insults are 
first the loss of the phenomenon itself and secondly of the emotion or material 
benefits derived from it” (p486) (86). Poor coping and low self-efficacy skills that 
accompany the grief and functional loss with COPD have been proposed to decrease 
the sense of self-mastery a person requires to optimally adjust to living with the 
disease and thus increases the likelihood of depressive symptomatology. Finally, 
Norwood proposes the level of social support that a person with COPD perceives (e.g. 
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social inclusion, marital status, having a carer) contributes to their resilience to 
depression (86). 
 
2.7 Treatment of anxiety and depression in people with COPD 
Despite anxiety and depression being major comorbidities in people with COPD, there 
are no standardised guidelines—either internationally or in Australia—for their 
treatment. The lack of research on the effectiveness of pharmacological and non-
pharmacological therapies used to treat anxiety and depression in COPD has 
contributed to the absence of clear recommendations for treatment in global 
guidelines. The only advice given in the recently updated GOLD guidelines published in 
2017 is that: “there is no evidence that anxiety and depression should be treated 
differently in the presence of COPD” (p117) (1). The current Australian and New 
Zealand COPD management guidelines merely state that there is “promising evidence” 
for the use of cognitive behavioural therapy (CBT) and medication prescribed by 
psychiatrists and psychologists for treating anxiety and depression symptomatology 
(93). With no standard procedures in place for the treatment of anxiety or depression 
in this population, the current management of these comorbidities is largely 
dependent on the discretion of the treating physician (Prof. Grant Waterer, personal 
communication with Dr. Natalie Strobel, 17 Feb 2012). In the general population, these 
psychological comorbidities are treated with either pharmacotherapy, psychotherapy 
or a combination of these two—with treatment being dependent on the severity of 
the psychological disorder and personal preference. These treatment options have also 
been applied in people with COPD, as well as the use of pulmonary rehabilitation and 
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relaxation therapy to manage anxiety disorders and depression, with mixed effects. 
The following section aims to summarise the treatment methods and the evidence 
surrounding their application in people with COPD.  
 
2.7.1 Pharmacotherapy 
Pharmacological interventions have long been used in standard clinical practice to 
treat anxiety and depression in the general population. The principal medications used 
to control symptoms include antidepressants (selective serotonin re-uptake inhibitors, 
tricyclic antidepressants and monoamine oxidase inhibitors), benzodiazepines, 
azapirones and less commonly, antipsychotic agents and anticonvulsants (94). Some of 
these medications have also been commonly applied in people with COPD, despite the 
lack of quality studies to assess their efficacy in this population. Of the few studies 
which have been conducted to determine the effects of pharmacological treatment of 
anxiety and depression in people with COPD, evidence remains equivocal. These 
studies have typically been fraught with differing sample sizes, large dropout rates 
and/or short follow-up periods. A Cochrane review conducted by Usmani et al. (2006) 
on the various pharmacological interventions used was unable to conclude on effective 
treatment options due to the sub-optimal quality of the research, noting the included 
studies (n=4) had small sample sizes, short follow-up periods and non-statistically 
significant results (95). Their review highlights the paucity of data with respect to 
quality randomised controlled trials. Previous researchers have identified numerous 
problems with the use of pharmacotherapy for the treatment of anxiety and 
depression in people with COPD, including: adverse side effects, misapprehension 
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about being stigmatised, non-compliant use of medication, negative previous 
experiences with pharmacotherapy, mistrusting the psychiatrist and side effects 
aggravating other comorbidities (96). Despite the lack of published evidence on the 
effectiveness of pharmacotherapy to treat anxiety disorders and depression in this 
population, it remains a common treatment option selected by treating physicians 
(Prof. Grant Waterer, personal communication with Dr. Natalie Strobel, 17 Feb 2012). 
 
2.7.2 Pulmonary rehabilitation  
Pulmonary rehabilitation is an “evidence-based, multidisciplinary, and comprehensive 
intervention for patients with chronic respiratory diseases who are symptomatic and 
often have decreased daily life activities” (p2) (97). The objective of pulmonary 
rehabilitation is to “reduce symptoms, optimize functional status, increase 
participation, and reduce health care costs” through exercise training, education, 
nutritional intervention and psychosocial support (p2) (97). There is an emerging body 
of literature on the effect of pulmonary rehabilitation to reduce symptoms of anxiety 
and depression in people with COPD (1, 98).  In the most recent meta-analysis 
available (n=6 studies), comprehensive pulmonary rehabilitation programs that 
incorporated exercise, education and social support reported significantly reduced 
anxiety and depression in people with COPD compared to standard care (98). 
However, there was large heterogeneity in the pulmonary rehabilitation programs, 
making it difficult to determine which aspects of the pulmonary rehabilitation program 
had the greatest impact on psychological symptomatology (98). 
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2.7.3 Self-management programs 
Self-management programs in people with COPD are defined as “structured but 
personalised and often multi-component, with goals of motivating, engaging and 
supporting the patients to positively adapt their health behaviour(s) and develop 
better skills to manage their disease” (p4) (99). Self-management programs have 
historically been developed for a variety of medical populations, employed in a variety 
of settings (e.g. clinical and primary care settings) using an array of mediums (e.g. 
video-based programs, Internet-based programs) and may or may not include support 
from a healthcare provider/team. To date, there are limited data available on the 
efficacy of self-management programs to treat anxiety and depression in people with 
COPD, as most self-management programs mainly focus on physiological outcomes 
and health-care use (100). However, results from a recent Cochrane review (n=29 
included studies) found self-management improved HRQoL in people with COPD 
compared to usual care, providing support for the use of this treatment to alleviate 
mental health disorders in this population (101). Growing support is also provided by 
two recent studies which specifically examined the benefits of a self-management 
program designed to treat anxiety and depression in people with COPD. The first, by 
Howard and Dupont (n=222) investigated a self-management ‘COPD breathlessness 
manual’ based on the principles of cognitive behavioural therapy, relative to usual 
care. Results indicated those who participated in the five week home-based self-
management intervention significantly decreased their anxiety and depression 
symptomatology at six months compared to usual care (38). The second, a study by 
Jiang and He (n=96) investigated an uncertainty management intervention in the form 
of an audio CD and self-help manual, complimented by telephone guidance provided 
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by a nurse against usual care. They found a significant reduction in anxiety and 
depression at 10 month follow-up in the intervention group compared to usual care 
(35). These promising studies highlight the need for continued research into the 
efficacy of self-management programs on psychological symptomatology in people 
with COPD. 
 
2.7.4 Self-help groups 
Self-help groups are typically small voluntary groups, structured for the mutual help of 
its members and are widely used by people with a chronic disease. Face-to-face social 
interaction in these groups is highly encouraged to facilitate the feeling of a helpful 
support network (94). The numerous benefits of self-help groups include enhanced 
perceived social support and associated psychological benefits which may stem from a 
general increase of positive emotions, a boost in self-esteem and feelings of control 
and stability of one’s environment (102, 103). Whilst self-help group sessions are often 
incorporated in pulmonary rehabilitation programs or self-management programs, 
there is a paucity of data on the effectiveness of the use of these groups in the 
literature. To date, there are no studies reporting the efficacy of an intervention that 
only consists of a self-help support group to treat anxiety and depression in people 
with COPD. 
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2.7.5 Psychotherapy 
2.7.5.1 Relaxation therapy  
The aim of relaxation therapy is to facilitate the relaxation response by effectively 
dealing with some of the physiological responses which may accompany feelings of 
anxiety, as well as increasing a person’s perception of self-control, and thus ultimately 
wellbeing (86). Regulation of the sympathetic nervous system and stimulation of 
certain regions of the hypothalamus which control the ‘flight or fight’ response is 
central to this relaxation response (104). Relaxation therapy encompasses an 
assortment of techniques including: breathing exercises, progressive muscle 
relaxation, isometric muscle relaxation, biofeedback, meditation and hypnosis. (94). 
Relaxation therapy has been found to be effective in reducing a range of symptoms 
(e.g. hypertension, pain and insomnia) in other chronic diseases such as cardiovascular 
disease and cancer (105). However, despite relaxation therapy often forming a 
component of pulmonary rehabilitation, cognitive behavioural therapy and self-
management programs in people with COPD, there is limited literature about the 
immediate and long-term effects of these techniques on reducing anxiety and 
depression in people with COPD. A recent meta-analysis of relaxation therapy in a 
COPD population conducted by Volpato et al. (2015) found a slight effect on improving 
psychological wellbeing but acknowledged “higher quality research is required” (p1) 
(106). 
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2.7.5.2 Cognitive Behavioural Therapy (CBT) 
CBT is a structured, psychological intervention whereby the participant works 
collaboratively with the therapist to identify the types and effects of thoughts, beliefs 
and interpretations of current symptoms, feeling states and/or problem areas (40). 
CBT combines both cognitive interventions (cognitive restructuring i.e. attempts to 
alter individual appraisals and thinking patterns) and behavioural interventions to 
reduce dysfunctional emotions and behaviours. Such therapies are used to change the 
way people think and act and to give them a sense of control and encourage 
engagement in coping (40). The use of CBT is effective in treating many mental health 
problems, and international guidelines recommend CBT as the treatment of choice for 
a range of anxiety and mood disorders in the general healthy population. CBT 
treatment of these psychological disorders assists participants to recognise and 
challenge the negative thinking patterns and irrational beliefs that typically fuel their 
psychological symptomatology. CBT generally runs over 12 weeks and can be 
conducted either individually or in groups of people who are experiencing the same 
problems (107). 
 
CBT has shown potential as a treatment to improve anxiety and depression in a variety 
of chronic illnesses including cancer (particularly lung and breast), diabetes mellitus 
and Parkinson’s disease (107-112). There is also promising evidence from a growing 
body of studies that suggests CBT can also help reduce symptoms of anxiety and 
depression in people with COPD. In a recent Cochrane review of psychological 
therapies for the treatment of anxiety disorders in people with COPD, the authors 
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reported there was some evidence CBT was effective in reducing anxiety 
symptomatology (113). However the substantial heterogeneity between the studies 
included in the analysis limited the ability to draw reliable conclusions. Support for the 
ability of CBT to reduce depression in COPD populations comes from another meta-
analysis which reported a small but significant improvement in depression but not 
anxiety for this type of intervention (114). Appendix 2.1 presents a summary of 18 
published studies that have examined the effect of CBT on COPD populations. The CBT 
sessions were highly variable, with some being conducted individually either by face-
to-face interview or by telephone, while others were conducted in a group, some as 
part of a comprehensive program and others conducted utilising the principles of self-
management. Duration of treatment varied from one CBT session to 16, and the 
majority of these studies utilised the HADS, BAI and/or BDI-II to screen for anxiety and 
depression in their COPD population.  The majority of studies found a CBT intervention 
significantly reduced symptomatology for anxiety and/or depression relative to the 
control group, whether that was treatment as usual, enhanced standard care, 
education interventions and/or exercise. In one study by Kunik et al. (2001), as little as 
a single intensive two hour session of group CBT was associated with a reduction in 
anxiety and depression symptomatology relative to an education-only intervention, 
suggesting minimal exposure to CBT is enough to elicit at least some improvement in 
psychological outcomes (26). CBT has also been demonstrated to maintain 
improvements long-term, with another study by Kunik et al. (2008) reporting a 
significant reduction in anxiety and depression at 12 months post-intervention (28), 
and a study by Livermore et al. (2010) reporting a significant reduction in anxiety at 18 
months post-intervention (33). However, the COPD participants recruited for the 
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studies conducted by Kunik et al. were predominately male and from a veterans 
hospital, thus limiting the generalisability of these results (26, 28). Broad applicability 
of such studies to COPD populations is also difficult due to differences in population 
groups between each study, including differences in the proportion of males to 
females, the mean age, COPD severity of participants and where they were sourced 
(e.g. primary vs secondary care patients).  Of the three studies that found CBT had no 
effect on anxiety and depression, two studies had extremely small sample sizes (n=8 
and n=18) and therefore underpowered to detect a statistically significant difference, 
the CBT treatment was quite demanding for all three studies (8 x 90 minute sessions, 6 
x 90 minute sessions and 10 x 60 minute sessions) and there was a very short follow-
up period (nil, 12 weeks and nil) (25, 44, 47). These reasons may partly explain why no 
effect was found.  
 
To date, there have been two studies conducted in Australia exploring the 
effectiveness of CBT in people with COPD. The first, by Livermore et al. (2010) 
recruited people with COPD who had undergone pulmonary rehabilitation (n=41) and 
randomised them into a CBT intervention whereby participants were individually 
administered weekly hour long sessions over four weeks (n=21) or a routine care group 
(n=20). Assessments were made at baseline, post-intervention and at six, 12 and 18 
month intervals. The study found significant reductions in anxiety and catastrophic 
cognitions in the CBT group at follow-up compared to usual care. Livermore also found 
the CBT group did not experience any panic attacks during follow-up whereas patients 
in the routine care group did (60%) (33). The second study by Walters et al. (2013) 
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recruited people with COPD from general practises (n=182) and investigated CBT in a 
self-management format where it was delivered via nurses over the telephone. 
Participants were randomised into a ‘telephone health monitoring’ group where they 
received CBT via 16 x 30 minute phone calls over a year or in to a control group which 
received usual care as provided by a GP and a regular monthly phone call. Assessments 
were made at baseline, 6 months and post-intervention. Those in the telephone health 
monitoring group had significantly reduced anxiety but not depression (36).  
 
Despite the promising efficacy of CBT in people with COPD, a common problem 
encountered by investigational studies are the relatively high attrition rates of up to 
27–47% reported (28, 32, 44). This is a problem as it may demonstrate the 
impracticality of conducting CBT sessions in COPD populations. Whilst not every study 
reported reasons for the attrition from CBT programs, of the few that did, competing 
illness and logistical problems with time and transportation were barriers reported (25, 
27, 28, 31, 44). There is a clear need to investigate the facilitators and barriers to 
people with COPD attending CBT in order to address these issues to develop a feasible 
treatment for this population. Furthermore, research into the benefits of self-
management CBT is warranted due to the limited literature currently available of its 
effectiveness.  
 
2.8 Theoretical Framework 
The cognitive behavioural model was adopted for this thesis. The cognitive behavioural 
model of panic has emerged as a widely accepted theory for onset of anxiety in people 
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with COPD. As the fundamental basis for this model stems from the idea that 
catastrophic cognitions (thoughts) are the cause of anxiety, and that these cognitions 
are misinterpretations which can be reversed, this model provides a compelling 
rationale for the use of CBT to treat this comorbidity. CBT is based upon the theory 
that thoughts affect feelings, which in turn has a flow-on effect on behaviours, which 
then consequently affects thoughts again in a constant cycle (Figure 2.1). 
 
 
Figure 2.1 Cognitive behavioural theory 
 
The cognitive behavioural theory suggests when CBT is applied in people with COPD, 
the negative feedback loop (Figure 2.2) of the dyspnoea-anxiety-dyspnoea cycle 
experienced by people with COPD, is interrupted.  
 
Thoughts 
Feelings 
Behaviours 
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Figure 2.2 The dyspnoea-anxiety-dyspnoea cycle 
 
CBT also has the potential to alleviate symptoms of depression commonly experienced 
by people living with COPD by restructuring pessimistic thought patterns and negative 
behaviours. The use of CBT in people with COPD aims to help participants recognise 
their dysfunctional thinking patterns and factors contributing to their anxiety and 
depression, and re-interpret their physiological and cognitive symptoms in a more 
positive manner.   
 
2.9 Summary 
Anxiety and depression are common comorbidities in people with COPD which 
contribute to greater morbidity and mortality. The cognitive behavioural model has 
emerged as a widely accepted theory for onset of psychological symptomatology in 
this population, and there is promising evidence to suggest CBT improves mental 
health outcomes by disrupting this cycle. However, there is a need for an alternative 
modality of CBT delivery for people with COPD suffering from anxiety and depression 
Induced 
shortness of 
breath 
Anxiety, 
panic attacks 
Increased 
shortness of 
breath and 
anxiety 
Reduced 
activity and 
fatigue 
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to overcome the logistical barriers reported by previous investigational studies. Thus, a 
novel home-based self-management CBT learning resource in a DVD format was 
developed with an accompanying manual. The primary aim of this thesis was to 
investigate the efficacy of CBT delivered as traditional group therapy with a reduced 
number of sessions, and this novel home-based self-management DVD resource 
compared to usual care, to improve anxiety and depression symptomatology. The 
secondary aim was to investigate the efficacy of these interventions on improvement 
in HRQoL. This thesis also sought to investigate the risk factors associated with 
psychological symptomatology, the most suitable tool(s) for screening anxiety and 
depression and to explore participants’ experiences of CBT to understand the enablers 
and disablers for people with COPD to successfully enrol and complete a course.   
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2.10 Appendix 
Appendix 2.1 Cognitive behavioural therapy in people with COPD 
Author Population 
and country 
Design Sample Treatment Delivery of 
CBT 
Psychological 
outcome 
measures 
Time-points Attrition 
rate 
Outcome* 
Lisansky & 
Clough 1996 
(44) 
Self-selected 
convenience 
sample, USA 
One-
group 
pre- and 
post-test 
 
n=8; mean age=70 (SD 
not specified); 
m=38%; f=63% 
1. CBT: 8 x 90 minute 
weekly sessions, (one 
group of 8) (n=8) 
Researchers 
and nurse  
Kellner’s 
Symptom 
Questionnaire 
(SQ)  
Pre- and post-
intervention 
31% 
 
No change in symptoms 
of anxiety disorders or 
depression post-
treatment 
Eiser et al. 
1997 (47) 
Outpatients, 
England 
Repeated 
measures 
pre-post 
n=18; intervention 
group: mean age=73 
(SD not specified), 
m=40%, f=60%; 
control group: mean 
age=71,  m=50%; f= 
50%  
1. CBT: 6 x 90 minute 
weekly  sessions (groups 
of 5–6) (n=10) 
2. Control: 6 x 6 minute 
walking tests & lung 
function tests per week, 
no psychotherapy 
(groups of 5–6) (n=8) 
Psychiatrist HADS 1. CBT: Pre- 
intervention, 
post 
intervention 
and follow-up 
at 12 weeks  
2. Control: 
Baseline, week 
2 and week 7 
10%  
 
No change in symptoms 
of anxiety or depression 
post-treatment 
Emery et al. 
1998 (25) 
Community 
participants via 
advertising and 
physician 
referral, USA 
RCT n=79;  
mean age=67±6.5; 
m=47%; f=53% 
1. Exercise, education 
and stress management: 
10 weeks of exercise, 16 
education and 10 x 1 
hour stress management 
sessions based on CBT 
(n=29) 
2. Education and stress 
management: 16 
education and 10 x 1 
hour stress management 
sessions based on CBT 
(n=25) 
3. Control: Waiting List 
(n=25) 
Clinical 
psychologist 
CES-D, The 
Bradburn-
Affect-Balance 
Scale, STAI, SCL-
90-R 
Pre- and post-
intervention 
11% Exercise, education and 
stress management 
group significantly 
decreased symptoms of 
anxiety and depression . 
Waiting List group also 
significantly decreased 
symptoms of 
depression.  
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Author Population 
and country 
Design Sample Treatment Delivery of 
CBT 
Psychological 
outcome 
measures 
Time-points Attrition 
rate 
Outcome* 
Kunik et al. 
2001 (26) 
Patients from a 
veteran hospital 
& advertising, 
USA 
Single 
blind RCT  
n=53;  
mean age =71±5.9;  
m=83%; f=17% 
 
 
1. CBT: 1 x 2 hour group 
session (6–10 
participants) and weekly 
phone calls for 6 weeks  
(n=21) 
2. Control: 1 x 2 hour 
education session 
(groups of 6–10) and 
weekly phone call for 6 
weeks (n=27) 
Gero -
psychiatrist and 
internist  
BAI, GDS,  
SF-36 
Pre- and post-
intervention 
9% 
 
CBT significantly 
decreased symptoms of 
anxiety and depression   
de Godoy & 
de Godoy 
2003 (27) 
Outpatients 
attending PR, 
Brazil 
Single 
blind RCT  
n=30; intervention 
group: mean age= 
62±14.9; m=86%, 
f=14%; control group: 
mean age=59±11.8, 
m=63%, f=37% 
1. PR: 12 week program, 
each week: 2 x 
physiotherapy sessions, 
2 x physical exercise 
sessions, 1 x CBT session 
(groups or individual not 
specified) and 1 x 
educational session 
p/month (n=14) 
2. Control: same as PR 
group with no CBT 
(n=16) 
Not specified  BAI, BDI Pre- and post-
intervention 
 
Not 
reported 
 
 
 
PR group with CBT 
significantly reduced 
symptoms of  anxiety 
and depression  
de Godoy et 
al. 2005 (48) 
Outpatients, 
Brazil 
Single 
blind RCT 
n=49, 
mean age not 
specified (all >50 
years), m=73%, f=27% 
12 week PR program: 
G1: 2 x weekly physical 
exercise sessions,  
weekly individual 
psychotherapy sessions, 
monthly group 
education sessions, 2 x 
weekly physical therapy 
(n=19) 
G2: Same as G1without 
physical therapy (n=16) 
G3: Same as G1 without 
individual 
psychotherapy (n=14) 
Psychologist BAI, BDI Pre- and post-
intervention 
Not 
reported 
Groups 1 and 2 
significantly reduced 
symptoms of anxiety 
and depression. Group 3 
significantly reduced 
symptoms of anxiety but 
not depression 
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Author Population 
and country 
Design Sample Treatment Delivery of 
CBT 
Psychological 
outcome 
measures 
Time-points Attrition 
rate 
Outcome* 
Kunik et al. 
2008 (28) 
Patients from a 
veteran hospital 
& advertising, 
USA 
Single 
blind RCT  
n=238; intervention 
group: 
mean age=66±10.1, 
m=97%, f=3%; control 
group: mean 
age=67±10.4,  m=96%, 
f=4% 
1. CBT: 8 x weekly 1 
hour group sessions (up 
to 10 participants) 
(n=118) 
2. Control: 8 x 1 hour 
sessions of COPD 
education (n=120) 
Psychology 
interns and 
post-doctoral 
fellow 
SF-36, BAI, BDI-
II 
 
Pre-
intervention, 4 
weeks, post-
intervention 
and follow-up 
at 4, 8 and 12 
months 
27%  
 
Both groups significantly 
reduced symptoms of 
anxiety disorders and 
depression post-
treatment. 
Improvements were 
maintained with no 
significant change during 
follow-up  
 
Heslop et al. 
2009 (29) 
Outpatients, 
England 
Repeated 
measures 
pre-post 
n=10; mean age=68 
(SD not specified); 
m=50%; f=50% 
1. CBT: Individual 
fortnightly sessions 
(length not specified), 
(average 4 sessions, 
range 2–13 sessions) 
(n=10) 
Respiratory 
nurse 
HADS Pre-
intervention 
and post-
intervention 
(varying 2-4 
weeks after 
intervention) 
Nil 
 
Significantly reduced 
symptoms of anxiety 
and depression 
Howard et al. 
2010 (30) 
Outpatients, 
England 
Repeated 
measures 
pre-post  
n=48; intervention 
group: mean 
age=70.9±9.6, m=60%, 
f=40%; control group: 
mean age=72.9±10.0, 
m=60%, f=40% 
1. Cognitive-behavioural 
breathlessness 
intervention: 4 x weekly 
2 hour sessions (groups 
of up to 10) 
Team consisting 
of a 
psychologist, 
respiratory 
clinical nurse 
specialist, 
health 
psychologist, 
physio-therapist 
and 
occupational 
therapist  
HADS Pre- and post-
intervention 
and follow-up 
at 6 weeks 
Not 
specified 
Significantly reduced 
symptoms of depression 
but not anxiety at post-
intervention and follow-
up 
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Author Population 
and country 
Design Sample Treatment Delivery of 
CBT 
Psychological 
outcome 
measures 
Time-points Attrition 
rate 
Outcome* 
Hynninen et 
al. 2010 (31) 
Outpatient 
pulmonary 
clinic and 
newspaper 
advertising, 
Norway   
RCT using 
matched 
pairs  
N=51; intervention 
group mean 
age=59±7.6; control 
group mean age= 
63±9.9; total m=50%, 
f=50% 
1. CBT: 7 x weekly 2 
hour group sessions (4–6 
participants) and phone 
call at 1 and 3 months 
post-treatment (n=25) 
2. Control: enhanced 
standard care for COPD 
(groups of 4–6) and 
phone call every two 
weeks during 
intervention period to 
monitor psychological 
status (n=26) 
Post-graduate 
psychology 
student 
BAI, BDI-II Pre-and post-
intervention 
and follow-up 
at 6 months 
17% 
 
CBT significantly 
reduced symptoms of 
anxiety and depression 
post-treatment 
compared to control 
group. Decrease in 
anxiety (but not 
depression) also 
maintained at follow-up 
for CBT group compared 
to control group 
Lamers et al. 
2010 (32) 
Patients from 
general 
practises, 
Netherlands 
RCT n=187; intervention 
group: mean 
age=71±6.3; m=62%, 
f=38%; control group: 
mean age=72±7.1, 
m=58%, f=42% 
1. Minimal Psychological 
Intervention with 
elements of CBT and 
self-management: 2–10 
visits depending on 
patient progress over a 
period of at most 3 
months (n=96) 
2. Control group: Care as 
usual (n=91) 
Nurse SCL-90-R, BDI Pre- and post- 
intervention (1 
week) and 
follow-up at 3 
and 9 months 
47% Minimal Psychological 
Intervention group 
significantly reduced 
symptoms of anxiety 
and depression at 9 
months compared to 
usual care 
Livermore et 
al. 2010 (33) 
Hospital 
outpatients and 
in-patients, 
Australia 
RCT n=41; intervention 
group mean 
age=73±6.4; control 
group mean age= 
74±8.1; total m=24%; 
f=76% 
1. CBT: 4 x 1 hour 
weekly individual 
sessions (n=21) 
2. Control: routine care 
(n=20) 
Researcher  ADIS-IV, HADS Pre- and post-
intervention 
and follow- up 
at 6, 12  and 18 
months 
15% Significantly reduced 
symptoms of anxiety 
and no experiences of 
panic attacks in CBT 
group compared to 
control at post- 
treatment and follow 
up.  
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Author Population 
and country 
Design Sample Treatment Delivery of 
CBT 
Psychological 
outcome 
measures 
Time-points Attrition 
rate 
Outcome* 
Kapella et al. 
2011 (34) 
Community 
participants via 
advertising, 
USA 
Mixed 
method  
n=23; phase 1 group: 
mean age=60±10.0, 
m=78%, f=22%; phase 
2 group: mean 
age=65±9.0; m=78%, 
f=22% 
1. Phase 1: 6 x 1 hour 
weekly CBT sessions 
(n=5) 
 2. Phase 2:  
CBT: 6 x 1 hour weekly 
sessions (n=9) or 6 x 
wellness education 
sessions (9) 
 
Specialised 
nurse  
POMS Pre- and post-
intervention  
One person 
dropped 
out 
Wellness education 
sessions significantly 
reduced symptoms of 
depression but not 
anxiety post- treatment 
compared to CBT 
Jiang and He 
2012 (35) 
Outpatients, 
China 
RCT n=96; intervention 
group: mean 
age=65±9.0, m=71%, 
f=29%; control group: 
mean age:65±8.1, 
m=68%, f=32% 
1. Uncertainty 
Management: 4 x 35 
minute telephone calls 
weekly based on CBT, 
last 2 calls used to guide 
participants through 
audio CD and self-help 
manual (n=50) 
2. Control group: 
standard care (n=50) 
Research nurse STAI, HADS 
Depression 
Subscale 
Pre- 
intervention 
and 10 month 
follow-up 
3% Uncertainty 
Management 
significantly reduced 
symptoms of anxiety 
and depression 
Walters et al. 
2013 (36) 
Patients from 
general 
practises, 
Australia 
Cluster 
RCT 
n=182; intervention 
group: mean 
age=68.2±7.9; m=54%, 
f=46%; control group: 
mean age= 67.3±7.6, 
m=51%, f=49%  
1. Telephone Cognitive 
Behavioural Health 
Monitoring: 16 x 30 
minute phone calls over 
12 months (n=90) 
2. Control group: Usual 
care as provided by a GP 
plus regular monthly 
phone call from research 
nurse (n=92) 
Community 
health nurses 
HADS, CES-D, 
Post-Traumatic 
Stress Disorder 
Checklist-
Civilian Version, 
SF-36 
Pre-
intervention, 6 
months and 
post-
intervention  
18% Telephone Health 
Monitoring significantly 
reduced symptoms of 
anxiety but not 
depression 
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Author Population 
and country 
Design Sample Treatment Delivery of 
CBT 
Psychological 
outcome 
measures 
Time-points Attrition 
rate 
Outcome* 
Blumenthal 
et al. 2014 
(37) 
Outpatients 
recruited from 
university 
hospitals, USA 
RCT n=326; intervention 
group: mean 
age=66±7.9, m=62%, 
f=38%; control group: 
mean age=66±8.7, 
m=60%, f=40% 
1. Telehealth Cognitive 
Behavioural Coping Skills 
Training: 12 x weekly 
telephone sessions 
followed by 2 x bi-
weekly sessions for 1 
month (total 14 sessions 
roughly 30 minutes in 
duration over 16 weeks) 
(n=162) 
2. Control Group: COPD 
education. Same as 
above (n=164) 
Clinical 
psychologists 
and health 
educators 
STAI, BDI-II, SF-
36? 
Pre-and post- 
intervention 
7% Telehealth Coping Skills 
Training significantly 
reduced symptoms of 
anxiety and depression 
compared to COPD 
education 
Howard & 
Dupont, 
2014 (38) 
 
Patients from 
GP practises, 
England 
Single 
blind RCT 
n=222; intervention 
group: mean 
age=71±10.4, m=56%, 
f=44%; control group: 
mean age=73±11.4, 
m=41%, f=59% 
1. Cognitive Behavioural 
Manual (n=112) 
2. Control: British Lung 
Foundation Information 
Booklets (n=110) 
Both groups encouraged 
to follow their program 
for 1 hour per day over 5 
weeks. 
 2 x telephone booster 
call sessions provided at 
weeks 3 and 6. 
Psychologists HADS Pre- and post- 
intervention, 
and follow-up 
at 6 months 
2% Cognitive Behavioural 
Manual significantly 
reduced symptoms of 
anxiety and depression 
at 6 months follow-up 
 
 
Bove et al., 
2016 (43) 
Outpatients, 
Denmark 
RCT n=66; intervention 
group: mean 
age=71±8.39; m=33%, 
f=67%; control group: 
mean age=70±8.73, 
m=33%, f=67% 
1. 1 x home-based CBT 
and psychoeducation 
session (mean duration 
of 1 hour) and 1 x 20 
minute telephone 
booster session 2 weeks 
after 
2. Control: standard care 
(n=33) 
 
Nurse HADS Pre- and post-
intervention 
and follow-up 
at 1 and 3 
months 
10% Home-based CBT and 
pschoeducation 
significantly reduced 
Symptoms of anxiety at 
post-treatment and 
follow-up 
BAI: Beck Anxiety Inventory; BDI: Beck Depression Inventory; CES-D: The Centre for Epidemiological Studies—Depression Inventory; GDS: Geriatric Depression Scale; HADS: Hospital Anxiety and 
Depression Scale; POMS: Profile of Mood States PR: Pulmonary Rehabilitation; SCL-90-R: The Hopkins Symptom Checklist;  STAI: The State-Trait Anxiety Inventory; RCT: Randomised Control Trial 
*Effect sizes not summarised due to unreported data and inconsistent coefficients used within the literature 
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 CHAPTER THREE  
 
Determinants of concomitant anxiety and depression in people with chronic 
obstructive pulmonary disease 
 
This manuscript was submitted for publication in the Journal of Psychosomatic 
Research on the 2nd of October 2017 and is currently under review.    
 
Tina Phan, Owen Carter, Grant Waterer, Li Ping Chung, Maxine Hawkins, Cobie Rudd, 
Mel Ziman & Natalie Strobel. Determinants of concomitant anxiety and depression in 
people with chronic obstructive pulmonary disease. Journal of Psychosomatic 
Research. (Submitted for review on 2 October 2017). 
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3 Study rationale 
 
People with chronic obstructive pulmonary disease (COPD) frequently suffer from both 
anxiety and depression. However, the literature surrounding determinants for having 
both these psychological comorbidities is limited. Furthermore, generalisability of 
results are constrained due to the populations sampled. The following chapter (Study 
One) seeks to investigate the determinants of concomitant anxiety and depression in a 
more representative sample of people with COPD than previously used. It was 
hypothesised previous risk factors identified separately for anxiety or depression in 
people with COPD were also shared risk factors for concomitant anxiety and 
depression.  
 
This study was cross-sectional in design, and utilised baseline data collected from the 
Breathing New Life study to provide a picture of prevalence in an Australian COPD 
population. In addition, we also assessed the association between demographic 
predictor variables and psychological symptomatology score using logistic regression. 
Three factors were found to increase the risk of having both anxiety and depression in 
our COPD cohort: younger age, previous history of psychological illness and greater 
number of non-psychological comorbidities.    
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 CHAPTER FOUR 
 
Discriminant validity of the Hospital Anxiety and Depression Scale, Beck Depression 
Inventory (II) and Beck Anxiety Inventory to confirmed clinical diagnosis of 
depression and anxiety in patients with chronic obstructive pulmonary disease 
 
This manuscript was submitted for publication in the journal Chronic Respiratory 
Disease on the 6th of May 2015, was invited for second review on the 11th of November 
2015 and resubmitted on the 1st of December 2015. It was accepted for publication on 
the 17th of December 2015 and available online ahead of print on the 3rd of March 
2016. 
 
Tina Phan, Owen Carter, Claire Adams, Grant Waterer, Li Ping Chung, Maxine Hawkins, 
Cobie Rudd, Mel Ziman & Natalie Strobel. Discriminant validity of the Hospital Anxiety 
and Depression Scale, Beck Depression Inventory (II) and Beck Anxiety Inventory to 
confirmed clinical diagnosis of depression and anxiety in patients with chronic 
obstructive pulmonary disease. Chron Respir Dis. 2016;13(3):220-228. 
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4 Study rationale 
 
There is a lack of recommendations for psychological comorbidity screening measures 
in the Global Initiative for Chronic Obstructive Lung Disease management guidelines, 
and despite being commonly used in people with chronic obstructive pulmonary 
disease (COPD), the Hospital Anxiety and Depression Scale (HADS) has only been 
validated for use in this population twice beforehand and not at all for the Beck 
Depression Inventory (BDI-II) and Beck Anxiety Inventory (BAI). The following chapter 
(Study Two) seeks to add to the limited body of literature by investigating the 
discriminant validity of the HADS with people diagnosed with COPD, and to examine 
the discriminant validity of the BDI-II and BAI as potential alternatives for this 
population. It was hypothesised the BDI-II and BAI may be better alternatives to 
screening people with COPD for psychological symptomology than the HADS.  
 
This study used a subset of people from the wider Breathing New Life study cohort 
who were randomised to additionally self-complete the HADS, followed by a 
structured clinical interview with a provisional psychologist conducting the Mini 
Neuropsychiatric Interview (MINI) at baseline. Results of this study did not replicate 
previously reported low sensitivity and specificity of the HADS depression subscale 
(HADS-D) in people with COPD. However, the HADS anxiety subscale (HADS-A) as well 
as the BDI-II and BAI produced acceptable sensitivity and specificity. 
Recommendations for simple modifications of the HADS-D to improve its sensitivity 
and specificity for depression are given. 
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4.1 Abstract 
Objectives 
To investigate the discriminant validity of commonly used depression and 
anxiety screening tools in order to determine the most suitable for patients with 
chronic obstructive pulmonary disease (COPD). 
 
Methods 
COPD patients (n=56) completed the Hospital Anxiety and Depression Scale (HADS), 
Beck Depression Inventory (BDI-II) and Beck Anxiety Inventory (BAI). These scores were 
compared to confirmed clinical diagnoses of depression and anxiety using the Mini 
Neuropsychiatric Interview (MINI).  
 
Results 
HADS-D sensitivity/specificity was 78/81%; BDI-II 89/77%; HADS-A 71/81%; and BAI 
89/62%. HADS-D sensitivity/specificity was improved (100/83%) with removal of Q4 ‘I 
feel as if I am slowed down’ and adjusted cut-off (≥5). Removal of BDI-II Q21 ‘Loss of 
interest in sex’ with adjusted cut-off ≥12 resulted in similar improvement (100/79%). 
No problematic items were identified for HADS-A or BAI.  
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Conclusions 
Previously reported low sensitivity/specificity of the HADS for COPD patients was not 
replicated. Furthermore, simple modifications of the HADS-D markedly improved 
sensitivity/specificity for depression. BDI-II, HADS-A and BAI produced acceptable 
sensitivity/specificity unmodified. Pending further research, for COPD patients we 
recommend continued use of the HADS-A with standard cut-off (≥8) and removal of Q4 
of the HADS-D with lower cut-off ≥5. 
 
4.2 Introduction 
Depression and anxiety are common comorbidities in patients diagnosed with chronic 
obstructive pulmonary disease (COPD), with benchmark prevalence estimates of 40% 
for depression and 36% for anxiety (10). Screening COPD patients for concomitant 
psychological distress is important as it has been found to contribute to poorer health 
outcomes across a number of domains, including: increased exacerbation rates, 
diminished exercise performance and functional mobility, reduced health-related 
quality of life, increased number of emergency hospital visits, increased 
hospitalisations, increased length of stay as an admitted patient, increased mortality 
rates and in general greater economic burden (14-17, 19, 20, 22). Consequently, 
European and Australasian COPD management guidelines recommend routine 
screening for depression and anxiety in COPD patients using the Hospital Anxiety and 
Depression Scale (HADS) (115, 116). Use of the HADS with COPD patients is 
widespread; being reported in at least 17 published studies (11, 16, 19, 41, 45, 47, 56, 
65-74). However, only two previous studies have investigated the discriminant validity 
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of the HADS with COPD populations and both cast doubt about its usefulness. Cheung 
et al. confirmed clinical diagnoses of anxiety disorders with 55 elderly New Zealand 
COPD patients using the Mini Neuropsychiatric Interview (MINI) and reported at the 
standard cut-off  ≥8 the HADS anxiety subscale (HADS-A) provided 
sensitivity/specificity of 36/90% and Area Under Curve (AUC) of 79% (45). They 
recommended a lower cut-off ≥4 that yielded an improved sensitivity/specificity of 
79/71%. Nowak et al. used the German version of the HADS depression subscale 
(HADS-D) to assess 259 Swiss COPD patients for depression, cross-referenced with 
diagnoses of depression co-morbidity noted in patients’ clinical records, and also 
reported low discriminant validity at the standard cut-off ≥8 (sensitivity/specificity 
25/84%; AUC 66%) (46). They recommended a lower optimal cut-off score of ≥5 but 
this still yielded fairly low sensitivity/specificity 62/63%. These results cast doubt over 
the appropriateness of using the HADS for patients with COPD. However, these results 
demand replication before any firm conclusions can be drawn. 
 
Potential alternatives to the HADS for COPD patients include the Beck Depression 
Inventory (II), also a popular research measure to screen COPD patients for depression, 
and the counterpart for anxiety, the Beck Anxiety Inventory (BAI). These tests are 
longer than the HADS, with 21 items each, compared to the 14 items in total for the 
HADS, but are well established and popular for screening COPD patients for studies 
involving cognitive behavioural therapy (26-28, 31). However, we are unaware of any 
studies that have established the discriminant validity of either the BDI-II or BAI in 
COPD patients. Therefore, the aims of the present study were to investigate the 
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discriminant validity of the HADS with patients diagnosed with COPD, and to examine 
the discriminant validity of the BDI-II and BAI as potential alternatives for this 
population.  
 
4.3 Method 
4.3.1 Sample  
Participants were outpatients attending community-based COPD clinics in Perth, 
Western Australia. Participants were excluded if they had a life expectancy of less than 
six months, were currently involved in another research study, had an illness 
exacerbation resulting in hospitalisation within the previous month, were not fluent in 
English, or were blind, deaf or diagnosed with dementia or Alzheimer’s disease. Ethics 
approval for the study was granted by Royal Perth Hospital, Edith Cowan University 
and the South Metropolitan Health Service Human Research ethics committees. We 
attempted to contact a list of 164 outpatients. Thirty-five individuals were un-
contactable because they were either deceased, discharged from the clinics, had 
disconnected telephones or we were unable to contact them after five separate 
attempts. Of the 129 successfully contacted, 27 did not meet our inclusion criteria and 
46 declined to participate, citing ill-health or ‘lack of time’. The final sample consisted 
of 56 patients with confirmed diagnosis of COPD by respiratory physicians who gave 
their informed consent to participate in the study, representing 34% of our original 
sampling pool, and a consent rate of 55% of contactable and eligible participants. The 
mean age of participants was 73.3 years (SD 8.9; range 50–91). There were more 
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females (58.9%) than males (41.1%) and the majority of participants were retired 
(73.2%) and married or in a de-facto relationship (69.7%) (Table 4.1).  
 
Table 4.1 Participant characteristics 
Characteristic N % 
Males 
Female 
23  
33 
41.1 
58.9 
Aboriginal or Torres Strait Islander 1 1.8 
Education   
 Up to 10 years of school 26 46.4 
 11 years and above 27 48.2 
 Other 3 5.4 
Marital status   
 Married/De-facto 39 69.7 
 Not in a current relationship 17 30.3 
Has a carer 41 73.2 
Occupation   
 Employed   4 7.2 
 Retired 41 73.2 
 Other 11 19.6 
GOLD stage   
     Mild 2 3.6 
     Moderate 18 32.1 
     Severe 25 44.6 
     Very severe 3 5.4 
     Missing 8 14.3 
 
 
4.3.2 Instruments 
Participants were asked to self-complete the HADS, BDI-II and BAI, followed 
immediately by a structured clinical interview with a provisional psychologist 
conducting the MINI. The MINI (v6.0.0) is considered a ‘gold standard’ in determining 
incidence of Axis I psychiatric disorders as per DSM-IV and ICD-10 criteria (117). The  
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provisional psychologist was blinded to the results of the other questionnaires before 
conducting the MINI.  
 
4.4 Statistical analyses 
Aggregated and item-by-item scores were examined for the HADS, BDI-II and BAI and 
compared to clinically-confirmed current major depression and any anxiety disorders 
(panic disorder, agoraphobia and generalised anxiety disorder) based upon MINI 
diagnostic criteria. The sensitivity, specificity, Youden’s index J, positive predictive 
value, negative predictive value, kappa coefficient and AUC values were calculated 
using the MINI as the clinical standard for the presence or absence of psychological 
comorbidity. Independent samples t-tests were also used to compare the mean HADS, 
BDI-II and BAI scores of participants in various groups. IBM SPSS (v22) was used for all 
statistical analyses. 
 
4.5 Results  
4.5.1 Depression  
Nine of 56 patients (16.1%) met the clinical diagnosis for major depression according 
to the MINI. The mean HADS-D and BDI-II scores for these patients are compared to 
others in Table 4.2.  
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Table 4.2 Proportions and averages of depression and anxiety scores for the MINI, 
HADS-D, HADS-A, BDI and BAI 
Depression Measure MINI HADS-D ≥8 BDI-II ≥14 
Prevalence 16% (95% CI ±10) 29% (95% CI: 11.8) 34% (95% CI: ±12.4) 
Average scores with 
depression 
- 12.33 (SD = 4.15) 32.44 (SD = 12.04) 
Average scores without 
depression 
- 4.34 (SD = 2.83)* 9.40 (SD = 8.21)* 
Anxiety Measure MINI HADS-A ≥8 BAI ≥8 
Prevalence  25% (95% CI 14–36%) 32% (95% CI: ±12.2) 48% (95% CI: ±13.1) 
Average scores with 
anxiety 
- 9.14 (SD = 4.07) 20.79 (SD = 12.63) 
Average scores without 
anxiety 
- 4.36 (SD = 4.03)* 8.60 (SD = 10.39)* 
*denotes statistically significant difference to participants with depression at p<0.001 
 
Both HADS-D and BDI-II scores were significantly different between participants with 
clinically confirmed depression compared to those without. AUC statistics for the 
HADS-D and BDI-II were both close to perfect (94.8%, p<0.001; 94.9%, p<0.001 
respectively). As can be seen in Table 4.3, the recommended HADS-D cut-off of ≥8 
identified 7 out of 9 (77.8%) true positive cases and 38 out of 47 (80.9%) true negative 
cases. Youden’s index J suggested a similar optimal cut-off of ≥7. The mean score of 
false positive cases was significantly lower (M = 9.38, SD = 1.30) than true positives (M 
= 13.86, SD = 3.29) (t(8.36)=-3.571, p=0.003). The recommended BDI-II cut-off ≥14 
identified 8 out of 9 (88.9%) true positive cases and 36 of 47 (76.6%) true negative 
cases. Youden’s index J suggested a similar optimal cut-off of ≥13. BDI-II true positives 
cases had a significantly higher mean score (M = 32.4, SD = 12.0) than the false 
negative cases (M = 22.5, SD = 5.6) (t(18)=-2.454, p=0.025).  
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An examination of each item of the HADS-D using independent samples t-tests 
identified the mean score for Question 4 ‘I feel as if I am slowed down’ as substanitally 
higher than all other items. This was the only item of the HADS-D for which no 
participant scored zero, and the only item for which there was no statistically 
significant difference in mean scores between those with clinically diagnosed 
depression (M = 2.56, SD = 0.73) and those without (M = 2.09, SD = 0.86) (t(54)=-1.544, 
p=0.128). The sensitivity and specificity of the HADS-D was therefore recalculated 
when excluding this item. With Question 4 excluded, Youden’s index J suggested an 
optimal cut-off of ≥5 which detected all true positive cases (100.0%) and 39 out of 47 
true negative cases (83.0%) within our sample (Table 4.3). True positive cases still had 
a significantly higher mean HADS-D score (M = 11.0, SD = 3.22) than false positive 
cases (M = 6.33, SD = 1.80) (t(14)=-3.694, p=0.002).  
 
Independent samples t-tests for each item of the BDI-II also highlighted Question 21.  
The mean score for Question 21 ‘Loss of interest in sex’ did not differ significantly 
between those with a clinical diagnosis of depression (M = 1.30, SD = 0.43) and those 
without (M = 1.32, SD = 1.92) (t(54)= -1.181, p=0.243). Therefore, the sensitivity and 
specificity of the BDI-II was recalculated to exclude Question 21. Upon removal of 
Question 21, Youden’s index J suggested an optimal cut-off of ≥12 that detected all 
true positive cases (100.0%) and 37 out of 47 true negative cases (78.7%) within our 
sample (Table 4.3). 
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Table 4.3 The sensitivity and specificity of the HADS-D, HADS-D excluding Question 4, 
BDI-II and BDI-II excluding Question 21 for detecting major depression in COPD 
patients (%) 
Cut-off points Sensitivity Specificity Youden’s 
index J 
PPV* NPV* 
HADS-D      
3 100.0 31.9 0.32 22.0 100 
4 100.0 46.8 0.47 26.5 100 
5 100.0 57.4 0.57 31.0 100 
6 100.0 74.5 0.75 42.9 100 
7** 100.0 78.7 0.79 47.4 100 
8 77.8 80.9 0.59 43.8 95.0 
9 77.8 85.1 0.63 50.0 95.2 
10 77.8 91.5 0.69 63.6 95.5 
11 55.6 95.7 0.51 71.4 91.8 
HADS-D ex Qu 4      
1 100.0 28.3 0.28 21.4 100 
2 100.0 47.8 0.48 27.3 100 
3 100.0 69.6 0.70 39.1 100 
4 100.0 78.3 0.78 47.4 100 
5** 100.0 82.6 0.83 52.9 100 
6 88.9 87.0 0.76 57.1 97.6 
7 77.8 93.5 0.71 70.0 95.7 
8 55.6 95.7 0.51 71.4 91.8 
9 55.6 97.8 0.54 83.3 92.0 
BDI-II      
9 100.0 63.8 0.64 34.6 100 
10 100.0 70.2 0.70 39.1 100 
11 100.0 70.2 0.70 39.1 100 
12 100.0 76.6 0.77 45.0 100 
13** 100.0 76.6 0.77 45.0 100 
14 88.9 76.6 0.66 42.1 97.3 
15 88.9 78.7 0.68 44.4 97.4 
16 88.9 78.7 0.68 44.4 97.4 
17 88.9 78.7 0.68 44.4 97.4 
BDI-II ex Qu 21      
8 100.0 61.7 0.62 33.3 100.0 
9 100.0 70.2 0.70 39.1 100.0 
10 100.0 74.5 0.75 42.9 100.0 
11 100.0 74.5 0.75 42.9 100.0 
12** 100.0 78.7 0.79 47.4 100.0 
13 88.9 78.7 0.68 44.4 97.4 
14 88.9 78.7 0.68 44.4 97.4 
15 88.9 80.9 0.70 47.1 97.4 
16 88.9 80.9 0.70 47.1 97.4 
    *Note: PPV: positive predictive value, NPV: negative predictive value **Optimal cut-off  
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4.5.2 Anxiety 
Fourteen of 56 patients (25.0%) met the MINI criteria for an anxiety disorder. This 
included 6 patients diagnosed with panic disorder, 5 with agoraphobia and 3 with 
generalised anxiety disorder. Table 4.2 shows the proportion and average scores of 
patients identified as meeting the diagnostic criteria for any anxiety disorder via the 
MINI and those meeting clinically relevant anxiety symptomatology via the HADS-A 
and BAI.  
 
Independent samples t-tests suggested both HADS-A and BAI scores were significantly 
different between participants with clinically confirmed anxiety disorders compared to 
those without. AUC statistics for the HADS-A and BAI were both in the ‘fair’ range 
(78.4%, p<0.01; and 78.5%, p<0.01 respectively). At the recommended cut-off ≥8 the 
HADS-A identified 10 out of 14 true positive cases (71.4%) and 34 out of 42 true 
negative cases (81.0%). With our sample Youden’s index J suggested an optimal cut-off 
of ≥9. There were no significant differences between the mean scores of true positives 
(M = 11.20, SD = 2.44) versus false positives (M = 11.38, SD = 2.62) (t(16)=0.146, 
p=0.885). With the recommended cut-off ≥8 the BAI identified 11 out of 14 true 
positive cases (78.6%) and 26 out of 42 true negative cases (61.9%).  For our sample, 
the optimal cut-off was ≥12, which maintained true positives at 78.6% but improved 
false negatives to 76.2% (Table 4.4). No significant differences in BAI score were found 
between true positive cases (M = 25.10, SD = 10.23) and false positive cases either (M 
= 18.44, SD = 11.01) (t(16)=-1.542, p=0.136). 
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Table 4.4 The sensitivity and specificity of the HADS-A and BAI for detecting anxiety in 
COPD participants 
Cut-off points Sensitivity Specificity Youden’s 
index J 
PPV NPV 
HADS-A      
5 85.7 64.3 0.50 44.4 93.1 
6 78.6 71.4 0.50 47.8 90.9 
7 71.4 78.6 0.50 52.6 89.2 
8 71.4 81.0 0.52 55.6 89.5 
9** 71.4 85.7 0.57 62.5 90.0 
10 64.3 85.7 0.50 60.0 87.8 
11 28.6 88.1 0.17 44.4 78.7 
12 14.3 90.5 0.05 33.3 76.0 
13 14.3  92.9 0.07 40.0 76.5 
BAI      
8 78.6 61.9 0.41 40.7 89.7 
9 78.6 71.4 0.50 47.8 90.9 
10 78.6 76.2 0.55 52.4 91.4 
11 78.6 76.2 0.55 52.4 91.4 
12** 78.6 76.2 0.55 52.4 91.4 
13 71.4 78.6 0.50 52.6 89.2 
14 71.4 81.0 0.52 55.6 89.5 
15 71.4 81.0 0.52 55.6 89.5 
16 71.4 81.0 0.52 55.6 89.5 
    *Note: PPV: positive predictive value, NPV: negative predictive value **Optimal cut-off 
 
An examination of the mean response to each question within the HADS-A revealed no 
conspicuously inflated items for COPD patients.  
 
Examining the mean response to each question within the BAI revealed Question 15 
‘Difficulty breathing’ was substantially higher than other items. However, the mean 
score for this question remained statistically different between those with clinically 
diagnosed anxiety (M = 1.71, SD = 1.07) and those without (M = 1.0, SD = 1.12) (t(54) = 
-2.05, p=0.045), suggesting discriminant validity still existed and removal of this item 
was therefore not warranted.  
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4.6 Discussion 
The first aim of this study was to investigate the discriminant validity of the HADS with 
patients diagnosed with COPD. We were unable to replicate the findings of Cheung et 
al. and Nowak et al. (45, 46). In contrast to Cheung et al., who found a much lower 
optimal cut-off for the HADS-A of ≥4, our optimal cut-off (≥9) was a very close 
approximation to the standard recommendation of ≥8. The reason for the different 
results is far from clear. The proportion of our sample diagnosed with anxiety disorders 
(25.0%) corresponded very closely with the sample of Cheung et al. (25.5%) using the 
same diagnostic test (MINI) and extremely similar patient profiles (Anglo-Saxon 
dominant cultures i.e., New Zealand v. Australia). So too, both studies had similar 
sample sizes (n=55 v. 56), demonstrated similar levels of discriminant validity (AUC 
79% v. 78.4%), and shared fair sensitivity (79% v. 71%) and specificity (71% v. 86%) at 
their optimal cut-offs. However, the COPD severity in the population studied by 
Cheung et al. was not reported, raising the question as to whether this may have 
affected prevalence rates which would ultimately impact on sensitivity and specificity 
scores. Cheung et al. acknowledged their optimal cut-off was ‘unusually low’ and 
further replication of their results was therefore warranted. The fact that we were 
unable to replicate their results now casts doubt over their suggestion of a HADS-A 
cut-off of ≥4 for COPD patients. Further attempts to replicate the results of Cheung et 
al. are needed to clarify this matter. 
 
Contrary to Nowak et al. who suggested the HADS-D provided poor discriminant 
validity for COPD patients (AUC 66.2%), our results suggested its discrimination was 
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excellent (AUC 94.8%). Even with their optimal cut-off ≥6, Nowak et al. observed a 
borderline sensitivity/specificity of 62.1/62.6% contrasting with our optimal cut-off ≥7 
achieving 100.0/78.7%, and improving even further with removal of Question 4 and 
lowering the cut-off to ≥5 yielding 100.0/83.0%. There are many possibilities why we 
were unable to replicate the results of Nowak et al., including vastly differing sample 
sizes (n=259 v. 56), differing prevalence of major depression (16.1% vs 11.2%), use of 
the German v. English version of the HADS, differing cultures and use of pre-diagnosed 
depression based on medical records subsequently confirmed by the patient’s 
physician v. current diagnosis confirmed by a psychologist using a structured clinical 
interview.  
 
Despite the HADS being created to avoid somatic symptom overlap with anxiety and 
depression in medical patients, the continued use of HADS with chronic diseases 
remains contentious as a variety of cut-offs have been suggested differing from 
optimal cut-off scores suggested for the general patient population e.g. HADS-D ≥4 in 
coronary heart disease (118) and HADS-D ≥11 in end-stage renal disease (119). Given 
that the discriminant validity of the HADS has only been tested in COPD populations 
three times with divergent results, the recommendation of using this screening tool in 
international management guidelines remains contentious. More population-specific 
tools, such as the Geriatric Anxiety Inventory and COPD Anxiety Questionnaire 
(German: CAF), may be preferable (120, 121). However, Cheung et al. investigated the 
Geriatric Anxiety Inventory as another alternative measure for use with COPD patients 
but found it no more useful than the HADS, and to the best of our knowledge the CAF 
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has yet to be translated and validated for use in English and we are unaware of any 
others for COPD.  
 
The second aim of our study was to examine the discriminant validity of the BDI-II and 
BAI as viable alternatives to the HADS for use with patients diagnosed with COPD. The 
BDI-II demonstrated excellent discriminant validity and very similar 
sensitivity/specificity to the HADS-D. Question 21 did not discriminate between those 
with and without clinical depression. However, its removal only marginally improved 
the validity of optimal cut-offs (J = 0.77 vs 0.79). Therefore we see little value in 
unnecessarily modifying the BDI-II for use with COPD patients. Likewise, the BAI 
demonstrated similar discriminant validity to the HADS-A. However, given the shorter 
length of the HADS (14 items combined) compared to the BDI-II and BAI (42 items 
combined) and the free use of the former, versus cost per test of the latter, there may 
be limited advantage of using the Beck inventories over the HADS. 
 
The relatively modest sample size of stable COPD patients in our study increases the 
probable error of our prevalence estimates. However, they were highly consistent with 
previous estimates, giving us some reassurance that they are reasonably 
representative. It is possible our study suffered selection bias; patients suffering 
poorer mental health may have been more motivated to participate, thus inflating our 
prevalence estimates.  Fortunately, we achieved a consent rate of 55% implying our 
data represent the majority of our sample, thereby reducing this potential for sampling 
error. Another potential limitation is that we did not exclude participation in 
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pulmonary rehabilitation as a possible confounder, which previous evidence suggests 
can be effective for reducing anxiety and depression in COPD patients (25, 122). 
Cheung et al. and Nowak et al. also failed to control for this, as such future studies 
should ensure that pulmonary rehabilitation is treated as a covariate. 
 
4.7 Clinical implications 
Since Question 4 from the HADS-D appears to be a universal symptom of COPD 
patients and our data suggests the removal of this question and lowering the cut-off to 
≥ 5 provides superior sensitivity and specificity, we recommend this course of action 
when using the HADS-D specifically with people diagnosed with COPD. As the HADS-A 
provided fair sensitivity and specificity and no items appeared to overlap with the 
symptomatology of COPD we recommend retaining the standard cut-off point of ≥8 for 
the HADS-A until such time as future studies suggest otherwise. Our results therefore 
support current guidelines of routine use of the HADS as a screening instrument for 
COPD patients, retaining the traditional HADS-A cut-off score of ≥8 whilst removing 
Question 4 for the HADS-D and using a lower cut-off score of ≥5.  
 
Our investigation into the validity of screening tools for use in a clinical setting further 
highlights the importance of appropriate follow-up measures for those that screen 
positive. However, due to the restrictive time-frame of these measures, it is possible 
that patients may feel depressed without being flagged as suffering from clinical levels 
and should therefore also be considered for follow-up. Our study found that those 
clinically diagnosed with depression via the MINI and also screened as having 
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depression symptomatology in both the HADS-D and BDI-II had significantly higher 
mean scores than those that did not screen positive. Whilst the proportion of true 
positive to false positive cases was too small to be able to draw any definitive 
conclusions, another avenue for future research which has very important implications 
for targeted screening and treatment may be to investigate the demographic and 
physiological differences (e.g. FEV1, 6MWT, number of exacerbations) in COPD 
patients which may help to distinguish between these two subgroups.  
 63 
 
 CHAPTER FIVE 
 
 A randomised controlled trial investigating the efficacy of cognitive behavioural 
therapy on the mental health of people with chronic obstructive pulmonary disease: 
the ‘Breathing New Life’ study 
 
This manuscript was submitted for publication in the journal Trials on the 21st of May 
2017 and is still currently under review.  
 
Tina Phan, Owen Carter, Grant Waterer, Li Ping Chung, Maxine Hawkins, Cobie Rudd, 
Mel Ziman, Johnny Lo & Natalie Strobel. A randomised controlled trial investigating the 
efficacy of cognitive behavioural therapy on the mental health of people with chronic 
obstructive pulmonary disease: the ‘Breathing New Life’ study. Trials. (Submitted for 
review on 21 May 2017)  
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5 Study rationale 
 
The following chapter (Study Three) seeks to investigate the efficacy of cognitive 
behavioural therapy (CBT) in addition to usual care for the treatment of anxiety and 
depression in people living with chronic obstructive pulmonary disease (COPD), 
compared to usual care alone. As investigational studies have commonly reported 
participants’ lack of transport, lack of time and illness as barriers to recruitment and 
successful completion, a novel self-management resource was developed in the format 
of a DVD with accompanying manual to overcome these issues. A randomised 
controlled trial was conducted to investigate the efficacy of CBT delivered via a 
traditional group therapy format with a reduced number of sessions (CBT) or a home-
based self-management DVD format (DVD) in reducing psychological symptomatology. 
The secondary aim was to investigate the efficacy of these CBT interventions to 
improve health-related quality of life (HRQoL) relative to usual care. It was 
hypothesised the CBT and DVD groups would have better mental health and HRQoL 
outcomes after 12 months compared to the usual care alone group, with the DVD 
group likely to have higher treatment compliance due to the nature of the resource.  
 
The study was a randomised controlled trial comparing two half-day group face-to-face 
CBT sessions with a one-hour telephone booster session and the six week ‘Breathing 
New Life’ home-based self-management CBT learning resource (DVD) and 
accompanying manual, relative to usual care alone.  Results of the study indicate there 
were no significant changes over time in anxiety, depression or HRQoL between any 
for our COPD study groups. 
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 CHAPTER SIX 
 
A qualitative investigation of the facilitators and barriers for people with chronic 
obstructive pulmonary disease to participate in cognitive behavioural therapy 
 
This manuscript was submitted for publication into Journal of Health Psychology on the 
13th of November 2017 and is currently under review. 
 
Tina Phan, Owen Carter, Grant Waterer, Li Ping Chung, Maxine Hawkins, Cobie Rudd & 
Natalie Strobel. A qualitative investigation of the facilitators and barriers for people 
with chronic obstructive pulmonary disease to participate in cognitive behavioural 
therapy. Journal of Health Psychology. (Submitted for review on 13 November 2017).  
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6 Study rationale 
 
Cognitive Behavioural Therapy (CBT) is a promising treatment option for people with 
COPD suffering from anxiety and depression, but many investigative studies report low 
recruitment and high attrition rates. The following chapter (Study Four) seeks to 
investigate the facilitators and barriers to successful completion of CBT delivered via 
face-to-face groups (CBT) or DVD (DVD) as reported in the previous chapter (Study 
Three), with the aim to improve future recruitment and retention.  
 
This is the first known qualitative study undertaken to specifically investigate the 
facilitators and barriers to uptake and completion of CBT in people with COPD. In-
depth interviews were conducted with a subset sample of people from the wider 
Breathing New Life study cohort. Transcriptions were analysed using a 
phenomenological approach. Key facilitators for traditional face-to-face group CBT 
included the social interaction, whilst for both modalities the ability to identify with 
other people suffering from COPD was important. Some DVD participants lacked the 
technical skills required to actively engage with technology and the accompanying 
manual. 
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 CHAPTER SEVEN 
 
7 GENERAL DISCUSSION 
 
7.1 Discussion 
This thesis was originally undertaken in response to a need suggested in the literature 
for greater accessibility to psychological treatment options for anxiety and depression 
for people living with chronic obstructive pulmonary disease (COPD). Building upon a 
promising body of literature demonstrating the efficacy of traditional face-to-face 
group cognitive behavioural therapy (CBT) for people with COPD, a novel, home-based 
self-management CBT resource in the form of a DVD with accompanying manual, was 
specifically developed for people with COPD. This resource was developed using 
considerable expertise from a multi-disciplinary team, including respiratory physicians, 
psychologists, physiotherapists, nurses, health consumer representatives and COPD 
patients themselves. A randomised controlled trial methodology was devised and 
undertaken to test the efficacy of this novel intervention compared to CBT delivered as 
shortened group sessions and care as usual defined as treatment prescribed by 
participants’ GPs. However, the study failed to establish the efficacy of either format of 
CBT to improve anxiety, depression or health-related quality of life (HRQoL). A number 
of possible explanations exist for why this thesis failed to replicate previous findings 
that demonstrated the efficacy of CBT for this cohort. Some explanations have already 
been discussed in Chapter Five but there are others that also need to be acknowledged 
in the context of this thesis. Given that the cognitive behavioural paradigm is well 
established in psychological science as an effective theoretical framework for the 
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treatment of anxiety and depression (123), it seems more likely that failure lay in the 
treatment modalities. In previous studies that conducted face-to-face CBT sessions 
with COPD populations, the number and length of sessions is highly variable, with the 
number of sessions ranging from 1–12 with an average of six sessions conducted 
between 90–120 minutes’ duration, with 120–720 minutes total time spent in sessions 
and 0–6 follow-up phone calls provided (Appendix 2.1). However, the number of face-
to-face CBT sessions in the present research was reduced to two 4.5 hour sessions, 
plus a single follow-up 1 hour telephone call, to reduce the demand on participants. 
Thus, the failure of the group CBT intervention to affect measurable improvements 
may be due to an insufficient number of sessions; two sessions plus a telephone call 
may not be enough for participants with COPD to establish measurable behavioural 
changes that reduce anxious and depressive thoughts and feelings. More sessions may 
be required but it is unclear exactly how many sessions would be optimal for a benefit 
to be seen whilst simultaneously reducing the burden of attending face-to-face 
sessions to prevent high drop-out rates in COPD participants. Furthermore, for those 
with concomitant anxiety and depression, the question of how many sessions are 
optimally required to treat both psychological conditions must also be considered, as 
the brief CBT intervention used in this thesis may not simply have been enough.  
 
The home-based self-management CBT intervention on DVD with accompanying 
manual was also developed to reduce the need to travel and was based upon two 
previous studies in people with COPD demonstrating positive mental health outcomes 
from CBT delivered via an audio CD and self-help manual, and via a manual alone (35, 
38). However, the present research was unable to demonstrate the efficacy of this six 
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week, self-paced, CBT intervention on DVD with accompanying manual. One possible 
reason why the home-based self-management intervention did not work may have 
been due to the lack of interactive support. Both studies which found a significant 
improvement on anxiety and depression had telephone support in addition to the self-
management resources. However, the DVD resource investigated in this thesis had no 
additional telephone coaching supplied—follow-up phone calls were only undertaken 
to monitor compliance. Self-management CBT may require additional personal support 
when delivered to people with COPD. Further investigation of  
self-management CBT resources in people with COPD are clearly required and 
should aim to compare the delivery of home-based self-management CBT resources 
whilst systematically varying telephone support to investigate whether this is the case.  
 
It is possible that the study was statistically underpowered due to its sample size. 
Increasing the sample size would undoubtedly have improved the chance of 
producing a statistically significant result but as previously discussed in Chapter Five, 
this difference would have been small (one point mean difference between groups on 
the BAI and BDI-II) raising the question whether the difference would translate into 
any practical, clinical meaningfulness. This highlights the importance of developing an 
intervention to achieve clinically meaningful outcomes so that the patient population 
directly benefits from noticeable improved symptomatology. It is also entirely possible 
that only two published manuscripts describing successful self-management CBT 
interventions for people with COPD exist so far due to  publication bias, evident where 
scientific journals are more likely to report statistically significant results and less likely 
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to publish results of studies with null hypotheses (124). Consequently, publication bias 
may also deter researchers from submitting their manuscripts with null hypotheses. 
Thus it is conceivable that other studies also found a lack of significant clinical 
improvements to psychological symptomatology using self-management CBT 
resources and this thesis was not alone in that conclusion, potentially explaining why a 
positive effect was not detected because this method of delivering CBT is not 
efficacious.  
 
Although no measurable benefit was detected for either of the CBT interventions used 
in the randomised controlled trial, the qualitative results from Study Four (Chapter Six) 
suggest participants perceived some value. This dissonance raises the question as to 
why their perceived value did not translate to quantifiable improvements in 
symptomatology scores. One possible explanation is that despite the interviewer’s 
best efforts to establish rapport and pursue in-depth lines of enquiry, the interviewed 
participants potentially remained too polite to complain about the interventions and 
the interviews suffered from a degree of socially desirable response bias. A second 
explanation is that the interviews suffered from response bias with participants who 
found the intervention helpful more likely to consent to participate in the interviews 
than those who found it unhelpful. Fortunately, a comparison of interviewed versus 
non-interviewed participants’ quantitative anxiety and depression measures is 
possible. If the former explanation was the case, then it would be expected that 
interviewed participants’ scores would differ little from non-interviewed participants’ 
scores. If the latter explanation is true then it would be expected that interviewed 
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participants’ scores would differ significantly from those not interviewed. As it turns 
out, interview participants had slightly, but significantly, lower anxiety scores and 
significant and substantially lower depression scores than their non-interviewed 
counterparts six months after the interventions—the time when the interviews took 
place (Table 7.1). These data support the theory that there was selection bias for the 
interviews, thereby providing a compelling explanation for the discord between the 
quantitative and qualitative results of the present dissertation. To overcome this 
limitation, future research would benefit from further stratifying the interview sample 
into groups of participants who objectively improved their psychological 
symptomatology. 
 
Table 7.1 Independent t-tests comparing 6-month post-intervention Beck Anxiety 
Inventory (BAI) and Beck Depression Inventory (BDI-II) mean scores of participants 
interviewed vs. not-interviewed 
Measure  Group Mean ± SD Mean difference  p-value 
BAI 
Interviewed 15.56 ± 8.88 
0.752 0.858 
Not-interviewed 16.31 ± 12.00 
     
BDI-II 
Interviewed 13.44 ± 8.16 
8.152 0.046 
Not-interviewed 21.60 ± 11.49 
 
 
Another possible cause of selection bias which future research would benefit from 
addressing is the differing stages of behaviour change in participants. The benefits 
reported by the subset of participants interviewed may not accurately reflect the 
opinions of all involved in the Breathing New Life study as those interviewed may have 
entered the study at a stage receptive to long-term behaviour change. Thus, as 
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outlined in the Transtheoretical model of behaviour change (125), these participants 
believed the CBT interventions helped them because they were open to the possibility. 
However, those not interviewed and the vast majority of participants may have 
inversely been in the ‘pre-contemplation’ stage with either no-to-little intention to 
change before entering the study or the ‘action’ stage where active efforts to change 
occurred but participants were unable to maintain these new positive behaviours and 
instead relapsed into a previous stage (125). Future research would benefit from 
building individual capacity for COPD participants to engage in their care by actually 
asking whether they are ready for change before involvement in CBT and investigating 
how best to support participants once enrolled, to maximise mental health outcomes.  
 
Due to the convenient nature of the DVD resource, it was hypothesised that 
compliance rates in the DVD group would be higher than those in the CBT group. 
However, comparable compliance rates were found that reinforced the opinions 
reported by participants in Study Four (Chapter Six) that the CBT treatments were 
sufficient in terms of setting, delivery, content, duration and number of sessions which 
were hypothesised as potential barriers. People with COPD appear to enjoy CBT and 
find it is a useful treatment approach once engaged. Recruiting participants in the first 
place remains a great hurdle. Findings from Study Four (Chapter Six) suggest that the 
best way to target this type of therapy to COPD populations is to describe the benefits 
of better breathing control skills gained and the importance of learning and benefitting 
from shared experiences with their peers.  
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The present research also specifically investigated the determinants for concomitant 
anxiety and depression in people with COPD in order to build a holistic picture of risk 
factors for this population which are currently lacking. As mentioned previously, it is 
somewhat surprising that the literature investigating risk factors has primarily treated 
the morbidity and mortality attributed to anxiety and depression independently, given 
that 22–48% of people with COPD are estimated to suffer from concomitant 
psychological symptomatology (61). The finding that people with COPD at a younger 
age are at greater risk of both anxiety and depression makes implicit sense. Receiving a 
diagnosis of an irreversible, progressive lung disease at a younger age would be more 
distressing than receiving the same diagnosis at an older age due to the life-long 
implications and greater loss potentially perceived by people of younger age. It would 
be advantageous for clinicians to be particularly mindful of their patient’s mental 
health when dealing with those diagnosed with COPD at a relatively younger age 
compared to most other patients. 
 
Lastly, findings of this thesis support the use of screening tools for psychological 
symptomatology in people with COPD. The commonly used screening measures in 
people with COPD tested for this thesis all demonstrated good discriminant validity 
with a structured clinical interview, with minor adjustments to the BDI-II and the 
Hospital Anxiety and Depression Scale (HADS) depression subscale further improving 
sensitivity and specificity. However, our results for the HADS remain equivocal as they 
contrasted with the two previous studies investigating this tool in people with COPD. 
Furthermore, the Beck inventories have yet to be validated for use in people with 
COPD despite their popularity as screening tools in COPD literature. Replication is the 
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cornerstone of the scientific method and future validation studies are clearly required 
to provide more clarity to this area.  
 
7.2 Thesis limitations 
The strengths and limitations of individual studies presented in this thesis have been 
discussed in each corresponding chapter. Thus, this section will focus on research 
limitations applicable to the greater research findings. As previously mentioned, some 
of the key strengths of this thesis are the use of a representative sample of people 
with COPD, validated and popular outcome measures to screen for clinically significant 
levels of anxiety and depression, and a randomised controlled design. Thus, readers 
can be assured the study findings are based on sound methodology. However, due to 
the nature of the study topic, it is possible this sample of people with COPD suffered 
from selection bias with those who were not anxious or depressed less likely to 
volunteer to participate or relate to the treatment options, or see the need for 
continued follow-up. There are limited solutions to control for this problem, thus 
readers should bear this in mind when interpreting the results of this thesis.  
 
Some may also argue the use of screening tools to examine the prevalence of clinically 
significant levels of anxiety and depression distress levels in our COPD cohort limits 
conclusions drawn due to their inability to provide a psychiatric diagnosis that comes 
from a structured clinical interview. However, whilst a diagnosis from a structured 
clinical interview that meets The Diagnostic and Statistical Manual of Mental Disorders 
or the International Classification of Diseases and Related Health Problems criteria is 
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considered gold standard, the use of these measures can be a costly and time-
intensive endeavour, hindering recruitment timelines. Study Two (Chapter Four) 
established the discriminant validity of the Beck inventories to the Mini 
Neuropsychiatric Interview and found they produced adequate sensitivity and 
specificity, thus providing confidence that the use of these screening tools was 
appropriate for our cohort. Furthermore, the Beck inventories are commonly used in 
previous studies and our use of these tools facilitates easy comparisons. Future studies 
may prefer to use structured clinical interviews to address these concerns.  
 
The randomised controlled trial (RCT) conducted for this thesis was based upon 
literature that seemed clear and consistent on the efficacy of brief interventions. As 
such, the study was based upon the best available evidence. The fact that this thesis 
was unable to replicate previous findings is useful science as it suggests the extant 
literature is less robust than previously thought. It may be seen as a limitation that no 
pilot study was conducted to collect preliminary data and information to adapt the CBT 
interventions for optimal success in the RCT. Conducting the qualitative investigation 
into the barriers and facilitators to CBT faced by people with COPD after the 
interventions were carried out also limited the range of data collected and subsequent 
opportunity to shape and inform the RCT for this dissertation. It would be of great 
benefit to ensure these factors are investigated prior to conduction of future CBT 
intervention studies to maximise study design for optimal success. 
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7.3 Concluding comments 
There is little doubt that anxiety and depression are common comorbidities in people 
with COPD which contribute to greater morbidity and mortality in an already 
vulnerable population. Globally, findings from this thesis confirm the importance of 
routine screening and treatment for anxiety and depression in people living with 
COPD, especially those diagnosed at a younger age and without prior psychological 
medical history. The HADS is recommended as a short, free and validated tool for such 
screening but clinicians might consider a simple adjustment to the HADS depression 
subscale, as outlined in Chapter Four. People with COPD tend to be sceptical about the 
potential benefit for CBT to improve their lives. However, CBT can be promoted to this 
cohort by emphasising that it is a non-pharmacological approach to symptom 
reduction, techniques are taught to control breathing and support can be gained from 
sharing experiences with other people suffering from COPD. It is the author’s hope 
that the research conducted as part of this thesis will eventually contribute to clear 
mental health recommendations in global guidelines for clinicians to refer to in order 
to improve the quality of life of people living with COPD.   
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